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1

Abstract

THORACENTESIS IN CARDIAC SURGERY PATIENTS WITH NON-SPECIFIC PLEURAL
EFFUSION: A CASE-CONTROL STUDY
David R. Kull, Barbara Stahl1, Gaetane C. Michaud3, Christina Carbone3, Kelsey Johnson3, Eileen Taylor2,
Vladimir Shumaster2, Ann Roselle2, Jonathan Puchalski3, Rowena Saga-Abrina2, and Umer M. Darr2
(Sponsored by Frank C. Detterbeck1).
Department of Surgery, Sections of Cardiac1 and Thoracic Surgery2; and Department of Medicine, Section
of Pulmonary and Critical Care Medicine3, Yale University, School of Medicine, New Haven, CT.
Non-specific pleural effusion is common in patients after cardiac surgery. Thoracentesis for nonspecific pleural effusion is being used more frequently with informal observations of improved dyspnea,
shorter length of inpatient stay (LOS), reduced need for escalation of care, and less postoperative atrial
fibrillation (AF). Our hypothesis is that the majority of cardiac surgery patients who undergo thoracentesis
for non-specific pleural effusion have improvements in dyspnea, reduced days in AF, and reduced
escalation of care compared to similar patients who do not have procedural intervention.
Our study population includes patients with evidence of pleural effusion on chest x-ray during a
period postoperative day (POD) 3 – 7, after cardiac surgery performed by a single surgeon at Yale - New
Haven Hospital, between Jan. 2013 and Dec. 2014. We have conducted a retrospective Case – Control
Study (n = 30, 15/15). Cases are defined as having thoracentesis POD3 – POD7 and are matched by age
and cardiac operation to Controls. We have recorded the frequency of improved dyspnea, as defined by ≥2
LPM reduction of daily peak O2 supplementation, after thoracentesis for Cases and compared this to the
same period for matched Controls. Postoperative LOS, incidence of AF, and requirement for escalation of
care are recorded and compared between Cases and Controls.
Dyspnea improved for 73% of Cases but this was not significantly different compared to Controls
during matched periods (11 vs. 7 patients, OR = 3.1, p = 0.14). Length of stay was not different between
Cases and Controls (6.7 vs. 5.8 days, p = 0.84) and there was no escalation of care required in either group
(95% CI, 0.00 – 0.14). There was no difference in the odds of postoperative AF between Cases and
Controls (OR = 0.22, p = 0.13). Patients who had thoracentesis performed before POD5 significantly lower
incidence of postoperative AF (0 vs. 6 patients, p = 0.01).
We have concluded that the majority of patients have improvement in dyspnea after thoracentesis for
non-specific pleural effusion after cardiac surgery. We observed that this improvement is not significantly
different than that experienced by similar control patients. Thoracentesis did not decrease length of stay.
Patients might experience fewer days in AF with thoracentesis when performed before POD5. Preoperative
risk factors for postoperative AF were not evaluated, could have introduced selection bias for Cases, and
therefore, limits this result.
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3

Introduction

3.1

Non-Specific Pleural Effusion in Cardiac Surgery Patients
Indications for Cardiac Surgery include some of the most common diseases in the United States:

including coronary artery disease, valvular heart disease, and other structural heart disease. Coronary
Artery Bypass Graft (CABG) for patients with coronary artery disease is one of the most common cardiac
surgical procedures and accounts for approximately 400,000 hospital discharges per year in the United
States[1]. Aortic Valve Repair (AVR) accounts for an additional 200,000 discharges in the United States
annually[2].

Limiting postoperative conditions that can prolong recovery after cardiac surgery has

importance in patient health and resource utilization.

Pleural effusions are often observed after uncomplicated cardiac surgery[3, 4]. It is estimated that
about half of patients undergoing cardiac surgery will have a postoperative pleural effusion about a week
after surgery[5]. The majority of these are small; characterized as blunting of the costophrenic angles with
less than 25% of the hemithorax occupied by pleural fluid[5]. The general course of a postoperative pleural
effusion has been described as bilateral initial appearance, unilateral (usually left-sided) maintenance at
one-week, with spontaneous resolution over time[3, 5, 6]. Such pleural effusions are generally considered
“non-specific” and thought not to require procedural intervention[7]. More recently, we have seen a limited
management paradigm shift toward procedural intervention [e.g. thoracentesis] for non-specific pleural
effusion at our institution.

3.2

Clinical Experience with Thoracentesis for Non-Specific Pleural Effusion
Non-specific pleural effusions are a frequent and clinically acceptable observation in patients

following cardiac surgery at Yale - New Haven Hospital. Approximately 2-years-ago, our Cardiac Surgery
service began to pursue thoracentesis for an escalating number of patients with non-specific pleural
effusion. This change in practice stemmed from the clinical observation that a subset of patients with
limited pulmonary reserve benefitted from removal of even small volumes of pleural fluid. The utility of
thoracentesis has never been formally studied in this population despite its increasing use at Yale – New
Haven Hospital.
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Mid-level providers from our Cardiac Surgery service have made informal observations of several
benefits with use of thoracentesis for non-specific pleural effusion. First, it is thought that patients with
limited pulmonary reserve and non-specific pleural effusion have improved dyspnea after thoracentesis
versus those who do not have procedural intervention. An interrelated observation is shorter hospital
length of stay. This has been attributed to improved dyspnea leading to better participation in inpatient
cardiac rehabilitation. Second, it has been informally noted that patients have fewer days of postoperative
AF after thoracentesis versus those with effusions who do not have procedural intervention.

This

observation is said to occur in the setting of similar anti-arrhythmic dosing for all patients with
postoperative AF. It is thought that decreased frequency of AF also shortens patient length of stay. Lastly,
our mid-level providers have reported that the requirement for escalation of care [e.g. transfer to a unit
providing a higher intensity of care] is less frequent in patients who have thoracentesis for pleural effusion
versus those who have not.

In order to better understand and characterize these observations, there are three questions that
might be addressed. First, how do non-specific pleural effusions develop after cardiac surgery? Second,
how might thoracentesis improve pulmonary dysfunction in these patients?
retrospective evidence to support the claims of benefit at our institution?

Third, is there formal
To address these, a

comprehensive review of the clinical literature is performed and summarized. The basic science literature
is also reviewed and a model for the pathogenesis of non-specific pleural effusion is proposed. Lastly, we
will perform a retrospective clinical study comparing outcomes of patients who had thoracentesis and
patients who did not have procedural intervention for non-specific pleural effusion after cardiac surgery.

3.3

Pulmonary Dysfunction and Recovery from Cardiac Surgery
Pleural effusion is one of several pulmonary complications with a potential to prolong recovery after

cardiac surgery[8]. In general, patients tend to have decreased respiratory function due to restrictive lung
changes following cardiac surgery[9]. Impaired chest wall mechanics seem to play a significant role in
restriction[9]. In a study of 18 cardiac surgery patients with normal preoperative pulmonary function
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testing (PFT) by Van Belle, et al; total lung capacity (TLC), 1-second forced expiratory volume (FEV1),
and functional residual capacity (FRC) were significantly impaired a week after surgery [(6.2 vs. 4.6L; p <
0.0001), (3.4 vs. 2.4L; p < 0.0001), (3.2 vs. 2.6L; p < 0.001) respectively][10]. The same study reported
significantly negative frequency dependent resistance by body-plethysmography, indicating an additional
component of airway obstruction[10]. The authors suggested that, in addition to impaired chest wall
mechanics, extravascular lung fluid and atelectasis likely play roles in decreased respiratory function[10].

The restrictive changes in ventilation associated with pleural effusion are generally proportional to
the size of the effusion[11, 12]. Perhaps the reason why non-specific pleural effusions are thought not to
require intervention is that they are characterized as small and have a tendency to spontaneously resolve.
But this generalization may be misleading in terms of predicting postoperative course after cardiac surgery.
In a large study of 2,892 patients by Labidi, et al, 192 patients (7%) were found to have “significant”
pleural effusions after cardiac surgery[4]. The term “significant” was not well defined and although the
majority had symptoms, not all patients were described as symptomatic[4]. Of the symptoms reported,
70% had shortness of breath, 56% had cough, 48% had bronchial secretions, 34% were tachypneic, and
23% had chest pain[4]. In this series, more than half of patients had small effusions occupying less than
25% of the hemithorax and 21% required multiple interventions[4]. The symptomology of small pleural
effusions tends to be similar to larger effusions. In a 29-case series of effusion occupying more than 25%
of the hemithorax by Rodriguez and Light, et al, 76% of patients with a large effusion complained of
shortness of breath, 10% complained of chest pain, and 3% complained of fever at 30-days[5, 13]. These
studies suggest that size is not proportional to symptoms.

Symptoms of pulmonary dysfunction after cardiac surgery are known to prolong hospital stay and
increase costs of care[8]. Pleural effusion has been shown as an independent risk factor for prolonged
recovery after cardiac surgery[3-6, 13, 14]. Labidi, et al, reported both longer ICU stay (142 ± 643 hrs
versus 35 ± 565 hrs; p < 0.05) and longer hospital stay (16.2 ± 20.9 versus 7.5 ± 8.6 days; p < 0.001) for
192 patients with pleural effusion requiring thoracentesis after cardiac surgery[4].

This same study

reported that the majority of patients had small pleural effusions occupying less than 25% of the
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hemithorax[4]. These data suggest that non-specific [e.g. small] pleural effusions may also be associated
with longer periods of stay and a higher intensity of care in the postoperative period.

3.4

Preoperative Risk Factors for Pleural Effusion
There is limited data on preoperative risk factors associated with pleural effusion after cardiac

surgery[4, 15]. In a study of 2,892 cardiac surgery patients by Labidi, et al, postoperative pleural effusion
was more prevalent in patients with comorbid diagnoses of congestive heart failure (9% vs. 4%), peripheral
vascular disease (22% vs. 11%) and atrial fibrillation (10% vs. 5%) versus those without effusion[4]. In
terms of heart failure, the preoperative ejection fractions (EF) for patients in the effusion group were
clinically similar (56% vs. 59%)[4]. The number of patients with an EF less than 40% was also slightly
higher in the effusion group (14% vs. 8%)[4]. Diuretics, anticoagulants, anti-platelet agents, and antiarrhythmic agents were also associated with pleural effusion in the Labidi study[4]. Whether preoperative
conditions or their management is more associated with developing postoperative pleural effusion remains
unclear.

However, Jensen and Yang found no association between preoperative heart failure and
postoperative pleural effusion in a retrospective study of 315 CABG patients[15]. Atrial fibrillation and
peripheral vascular disease were not among diagnoses investigated in this study[15]. From a more practical
standpoint, the attributable risks for postoperative pleural effusion in terms of the comorbidities studied are
low in both studies[4, 15]. The number of patients included in the Labidi study was an order of magnitude
larger than the Jensen study, which may have been why they had more statistically significant
differences[4, 15]. One criticism that we find with the Labidi study is the number of comparisons made
without correction for the family-wise error rate. Perhaps using a Bonferroni or other corrective method
would have reduced the number of significant differences. If there were a causal relationship between
preoperative comorbidities and postoperative pleural effusion, the attributable risks are small in the best
studies available.

Page 11 of 67

3.5

Intraoperative Risk Factors for Pleural Effusion
3.5.1

Topical Hypothermia

Topical hypothermia is thought to provide a cardio-protective benefit during surgery but it is now
used less frequently due to concern over pulmonary complications[16-19].

Myocardial hypothermia

decreases cellular metabolism, prevents cellular damage from anoxia, and reduces the rigidity of
contraction[16]. A study by Allen, et al, of 150 nonrandomized consecutive patients showed that topical
hypothermia with ice-slush versus no cooling was associated with an increase in postoperative pleural
effusion prior to discharge (RR = 2.8, p < 0.05)[17]. The ice-slush technique also was associated with
increased length of stay (11.2 vs. 8.5 days; p < 0.05)[17]. Intraoperative ice-slush was also associated with
postoperative pleural effusion in a study of 505 nonrandomized consecutive patients by Nikas, et al (RR =
2.4, p < 0.0001)[18].

These patients also received concurrent systemic hypothermia and cold

cardioplegia[18]. Authors in both studies concluded that phrenic nerve dysfunction results in atelectasis
which then leads to pleural effusion[17, 18].

Intraoperative stretch injury was also proposed as a

mechanism for phrenic nerve dysfunction by these authors as a similar cause of atelectasis and subsequent
pleural effusion[19, 20].

Pleural effusion in patients with true diaphragm paralysis (e.g. myasthenia gravis) has been
demonstrated in ICU patients[21]. How this exactly occurs has also not been fully described. One
explanation is that elevation of the hemi-diaphragm by elastic recoil of local lung segments attached to the
visceral pleura may increase negative pressure in the adjacent pleural space[22]. Mechanically increasing
negative pressure in the pleural space would potentiate the hydrostatic driving force for fluid filtration[23].
If filtration exceeds drainage, pleural effusion results.

An alternative explanation might be

ventilation/perfusion changes in collapsed lung segments leading to localized hypoxemia and lung edema.
The ensuing inflammatory response may increase the permeability of the visceral pleura[23, 24]. This
would lead to a functional connection between lung and pleural compartments not present in the normal
physiologic state[23]. Rising interstitial fluid pressure in the lung would first cause alveolar collapse (e.g.
atelectasis). At a certain threshold based on the relative permeability of the visceral pleura, fluid will
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overflow causing increased fluid filtration into the pleural space[23].

If fluid filtration overwhelms

lymphatic drainage of the pleural space, effusion will develop.

One point of contention for the topical hypothermia data is whether or not phrenic nerve
dysfunction is present at all[25]. In a study by Wilcox, et al, 93% of 52 postoperative patients receiving
topical hypothermia developed left lung atelectasis but less than 10% were found to have unequivocal
phrenic nerve dysfunction in the early postoperative period[25]. Multivariate analysis of intraoperative
factors showed that number of grafts, operative time, bypass time, opening of the pleura, non-use of a right
atrial drain, non-use of a polystyrene shield, and body temperature were predictive for the degree of left
lower lobe atelectasis[25].

If there is no disruption of phrenic nerve function but atelectasis and pleural

effusion still occurs, then another mechanism is implicated.

Inflammation might better explain both the development of atelectasis and it’s relationship with
pleural effusion. Although the association between topical hypothermia, atelectasis, and pleural effusion is
strong, its interdependence on diaphragm paralysis is less convincing. Cardiopulmonary bypass, aortic
cross-clamp time, and positive end expiratory pressure during postoperative mechanical ventilation are also
associated with lung injury and inflammatory changes[26, 27]. Similarly, these risk factors are associated
with atelectasis and pleural effusion[26, 27]. Exactly how lung injury would be potentiated by topical
hypothermia is unclear. It is possible that the use of topical hypothermia might be a confounder for factors
that are also strongly associated with pleural effusion. In fact, the Nikas study found that cross-clamp time
was elevated (49 vs. 43 min) for those receiving topic hypothermia[18]. The routine use of topical
hypothermia is no longer standard of care due, in part, to its relationship with pulmonary complications.
However, reexamining these data has been valuable in understanding the plausibility of lung inflammation
as part of the pathogenesis of pleural effusion.

3.5.2

Cardiopulmonary Bypass

Another intraoperative risk factor associated with pleural effusion is cardiopulmonary bypass
(CPB)[8]. Volume overload in the setting of CPB has been thought an obvious iatrogenic insult because: a)
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patients receive an average of 3-4L of crystalloid and colloid fluids during cardiac surgery; b) patients can
present with some degree of preoperative fluid overload in the setting of heart failure; c) comorbid renal
disease is a common presentation for these patients; and d) pleural effusion is common after cardiac
surgery[4, 9, 28, 29]. Pulmonary edema is also associated with CPB[8, 30-33]. It has been suggested that
the pathogenesis of pulmonary edema and pleural effusion may be interrelated.[8].

Intravascular hydrostatic forces associated with volume overload may cause both pulmonary
edema and pleural effusion[34]. The lung and pleural spaces are separate compartments in the normal
physiologic state[23]. In volume overload, elevated pulmonary capillary pressure can exceed osmotic
counter pressure in the lung interstitium[34]. This drives fluid into the lung interstitium. Under normal
circumstances, lymphatic drainage functions as a recruitable homeostatic mechanism for recovery[23].
Fluid accumulates when the lymphatic reserve capacity to clear fluid from the lung interstitium is
overwhelmed[23, 34]. Pulmonary edema can occur rapidly because the lung compartment is relatively
non-compliant[23]. The pleural space accumulates fluid by a similar mechanism[34]. Pulmonary and
central venous pressures are elevated in the setting of volume overload and this increases the filtration rate
of pleural fluid[23].

When the osmotic counter pressure and lymphatic clearance reserves are

overwhelmed, pleural effusion results[34].

Volume overload may only be part of a more complete explanation for pleural effusion after
cardiac surgery. In a study of 10 patients by Hachenberg, et al, intra-thoracic thoracic blood volume
(ITBV), pulmonary blood volume (PBV), and extravascular lung water (EVLW) were found to be elevated
immediately following separation from CPB[29]. However, at 4-hrs and 24-hours after separation, ITBV
and PBV remained elevated while EVLW decreased to preoperative levels[29]. The authors concluded that
postoperative hypoxemia resulting from fluid overload was not due to pulmonary edema and that
homeostatic mechanisms were maintained after CPB[29]. Both the lung and pleural compartments restore
homeostatic fluid balance through recruitment of the lymphatic system[23]. If the homeostatic mechanism
for recovery from pulmonary edema is maintained, it is reasonable to assume that this is also maintained in
the pleural space [e.g. the lymphatics are not interrupted].
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How pleural effusion still develops if there is relative capacity for fluid clearance requires further
consideration. The observation that EVLW is reduced within 4-hours of separation from CPB (detailed
above) might represent evidence for a non-physiologic lung compartment drainage mechanism that is not
recruitable by the pleural compartment[29]. One explanation proposed in chronic heart failure models is
that there is a pathophysiologic connection developing between the lung and pleural compartments [e.g. the
relative permeability of the visceral pleura increases][23]. By this mechanism, EVLW would be reduced as
pleural fluid filtration increases.

Wiener-Kronish, et al, demonstrated that lung edema induced by

inflammatory lung injury resolves by drainage into the pleural space through the visceral pleura in
sheep[35, 36].

Another explanation may be that the lymphatics of the pleural space are selectively

interrupted by an IMA takedown. However, there is no evidence to suggest that pleural effusion lateralizes
to the side of IMA takedown[37].

Inflammatory changes in the lung have been proposed to increase the permeability of the visceral
pleura[23, 35, 36]. Acute systemic inflammation and lung inflammation have been shown a consequence
of CPB[30-33].

Intubation with positive pressure ventilation is another source of inflammation and

pulmonary dysfunction[38]. The Alveolar-arterial (A-a) gradient is more severe after CPB than general
surgical procedures, which suggests a higher degree of lung injury and shunt fraction after CPB[39]. The
presence of inflammatory mediators in bronchoalveolar lavage (BAL) fluids after separation from CPB also
supports local lung inflammation[26]. Markers of systemic inflammation including compliment activation
and leukocyte activation have been shown in patients during and immediately after separation from
CPB[40, 41]. The compelling evidence for the association between CPB, lung, and systemic inflammatory
changes makes it a more reasonable explanation for the contribution of volume overload to pleural
effusion.

3.5.3

Surgical Trauma and Pleurotomy

Direct surgical trauma to the pleura has also been identified as a risk factor for postoperative
pleural effusion. Patients who undergo CABG using left internal mammary artery (LIMA) grafting versus
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saphenous vein grafting (SVG) techniques have been shown to be at greater risk for pleural injury[42-44].
The risk of opening the pleura is higher during IMA takedowns and therefore, it has been identified as an
iatrogenic source of pleurotomy[42].

In a study comparing 200 patients by Hurlbut, et al, a significantly larger proportion of patients
having undergone LIMA takedown manifested pleural effusion on POD6 versus those who had a
saphenous vein graft (84% vs. 47%, p < 0.05)[42]. Among symptomatic patients, the amount of fluid
removed was also larger (1,413 vs. 1,028 mL; p < 0.01) and this group had a significantly higher
requirement for re-intervention with thoracentesis (4% vs. 0%, p = NR)[42]. There was no difference in
atelectasis between the two groups at various perioperative time intervals[42].

Shielding of the

myocardium with a cooling jacket and use of a phrenic nerve shield was employed to avoid myocardial
damage and avoid postoperative phrenic nerve associated atelectasis[42]. Another study by Jain, et al, of
152 patients showed similar results for development of postoperative pleural effusion in LIMA versus SVG
techniques (55% vs. 35%, p < 0.05)[44]. A third prospective study by Ali, et al, of 280 nonrandomized
patients showed a significantly higher number of POD3 pleural effusions for LIMA takedown patients
where the pleura were surgically violated, versus those in whom the pleura was left intact (5% vs. 20%, p <
0.05)[43]. However, in another study of 30 patients, Vargas, et al, found no association between surgical
violation of the pleura and the development of pleural effusion[14]. One consideration for this finding
might be the relatively few patients studied.

There is further cytological evidence for pleural violation as a risk factor for the development of
postoperative effusion in CABG patients. In a study of pleural fluid from symptomatic patients postCABG with IMA takedowns, Sadikot, et al, observed a mean red blood cell count of 706 X 1012/L,
corresponding to a hematocrit of approximately 5%[37]. Further support for the finding of bloody effusion
was described in Labidi’s study for symptomatic effusion patients prior to POD15[4]. The type of surgical
procedure was not reported for those patients in whom pleural fluid was analyzed and no reference is made
as to what proportion had violation of their pleura[4]. A hemothorax is defined as a pleural effusion with a
hematocrit of >50% of the blood hematocrit[45, 46]. If the approximate observed hematocrit in these
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patients is around 5%, we can assume that there is an additional source of fluid effusion. Sadikot observed
early pleural effusions as exudative by Light’s Criteria with an approximate hematocrit of 5%[37].
Therefore, it would be reasonable to think that there is another process causing dilution. It is yet unknown
exactly how this occurs, whether at the site of pleurotomy or by another mechanism such as increased
pleural fluid filtration.

From the current clinical literature, we can speculate that the major contributing etiologies for
pleural effusion after cardiac surgery are intraoperative in nature.

These etiologies are CPB and

pleurotomy. Preoperative risk factors, if contributory, seem to have a small attributable risk. The broader
mechanism for the contribution of CPB to pleural effusion is volume overload in the setting of an
inflammatory response to lung injury. Pleurotomy is also a potential modifying effect for developing
pleural effusion whereby pleural injury and bleeding result in increased fluid filtration into the pleural
space. The common pathogenesis for pleural effusion from these risk factors suggests interrelated lung and
pleural inflammation.
elaborates this further.

A review of the current basic science research hereafter details evidence that
This evidence is summarized into a more comprehensive model for the

inflammatory pathogenesis of pleural effusion after cardiac surgery. A comprehensive understanding of
the pathogenesis for pleural effusion after cardiac surgery would be useful in evaluating therapies to
address this condition, including thoracentesis.

3.6

Pathogenesis for Non-Specific Pleural Effusion after Cardiac Surgery
Inflammatory processes are the underlying basis for many physiologic and pathologic

processes[47]. Given the proximity of the serous pleural layers to local the microcirculation, experts
speculate that the number of immune cells normally present in the pleural space represent an ongoing
physiologic inflammatory process[24]. There is general agreement that the pathologic processes that
underpin most etiologies of pleural effusion [e.g. parapneumonic, asbestosis, etc.] are inflammatory in
nature[24].

Cytologic characterizations of inflammation have already been described for several

conditions[24]. These include complicated parapneumonic effusion/empyema, tuberculosis, asbestosis,
pleurisy, malignant mesothelioma, metastatic carcinomatosis, and pleurodesis[24].

The inflammatory
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processes associated with non-specific pleural effusion after cardiac surgery has not yet been fully
described. Based on the current literature, we can build a broad framework of pleural inflammation for
effusion in this clinical setting.

3.6.1

Inflammation: Physiologic Response and Pathologic Consequences

Medzhitov’s 2008 Nature Review Article frames inflammation in terms of inflammatory triggers
that lead to a purposeful physiologic response[47]. These physiologic responses are generalized. In some
circumstances they can have consequences that result in pathology[47]. One example is tissue injury
leading to inflammation as a tissue repair response[47]. The consequences of this response that are
occasionally observed are fibrosis, metaplasia, or sometimes neoplasia[47].

Another example is

physiologic tissue stress or malfunction that leads to inflammation as an adaptation to stress and restoration
of a homeostatic state[47]. Occasionally, clinicians observe shifts in the original homeostatic set points,
diseases of homeostasis [e.g. insulin insensitivity/DM2], or autoimmune diseases[47].

According to Medzhitov’s framework, large ranges of mediators that form complex regulatory
networks would coordinate inflammatory responses[47]. One approach to understanding these complex
networks is to break them down into individual processes characterized by inducers, sensors, mediators,
and effectors[47]. As an inciting signal, endogenous inducers [e.g. surgically altered tissues, edema] would
require a sensing mechanism to propagate a response[47]. Modulation of sensors can lead to expression
and/or de-sequestration of mediators that ultimately act on effectors[47]. Mediators can be cell derived,
tissue derived, plasma derived or derived from the extracellular matrix (ECM) [47]. Effectors can also be
cells, tissues, plasma, or the ECM[47]. A process associated with an inflammatory response can
simultaneously interact with other sub-routines as a network[47]. Further, processes can interact in series
as part of an ongoing response[47]. These interactions are thought to be governed by the balance between
pro- and anti-inflammatory signals[47]. In so much as pro-inflammatory signals can lead to physiologic
responses such as tissue repair and alterations in homeostasis, anti-inflammatory signals have the potential
to lead to resolution of inflammation or return to physiologic homeostatic set points[47].

Page 18 of 67

3.6.2

Lung Injury, Inflammation and Non-Specific Pleural Effusion

Pleurotomy is a traumatic inflammatory trigger for pleural repair. The most obvious inducer to be
considered is the surgically induced epithelial-mesenchymal interaction[47].

Epithelial cells are

physiologically separated from mesenchymal cells by a basement membrane[47]. The sensors associated
with connecting these two tissue layers are poorly characterized. However, some evidence supports pleural
tissue macrophages (pMϕ) as having a large role in coordinating the inflammatory response[48]. pMϕ have
been shown to produce significant quantities of the chemokine mediators interleukin-1β (IL-1β) and tumor
necrosis factor-α (TNF-α) in murine pleurisy models[49]. IL-1β and TNF-α were further shown to induce
mesothelial cells to produce the mediators macrophage chemo-attractant protein-1 (MCP-1), macrophage
inflammatory protein-1α (MIP-1α), MIP-2, KC and IL-8[48]. These chemokine mediators are known to
recruit effector polymorphonuclear neutrophils (PMNs) to damaged tissues from the plasma pool[48].

Volume overload in the setting of CPB may cause increased fluid filtration into the pleural
space[28]. Increased visceral pleura permeability in the setting of lung injury may potentiate this effect.
Massoudy, et al, demonstrated the lung as an ongoing site of platelet sequestration, retention of activated
PMNs, and production of cytokines (IL-6, IL-8)[30]. They were able to assess this through right atrial
(RA) and pulmonary vein (PV) sampling before and after pulmonary passage [e.g. removal of cross clamp
during CPB[30]. Sampling of BAL fluid after separation from CPB also supports the presence of these
cytokines in increased concentration compared to plasma[26]. Retention of leukocytes in the pulmonary
vasculature following pulmonary passage, combined with elevated cytokines, indicates that exposure of the
sub-endothelial ECM is one potential inducer. Factor XII senses vascular endothelial damage through
activation; this occurs through contact with collagen and the ECM[47]. Activated factor XII initiates the
four proteolytic cascades known to generate the acute phase response[47]. The tunica media of blood
vessels secretes IL-6 as a pro-inflammatory cytokine in response to endothelial damage[50].

The increased levels of IL-6 shown in the Massoudy study are of some interest[30]. Endothelial
cells are important effectors for IL-6/sIL-6α (soluble IL-6) in that they increase expression of intracellular
adhesion molecule 1 (ICAM-1)[51]. ICAM-1 expression enables endothelial cell regulation of leukocyte
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recruitment[51]. Additionally, IL-6 promotes the redistribution of VE-cadherin on endothelial cells[51].
This redistribution increases vascular permeability[51]. Moreover, the role of IL-6 is actively being studied
for its contribution to the progression of malignant ascites in ovarian cancer and its effect on peritoneal
permeability[51]. This interaction may be an important promoter of capillary leakage, pulmonary edema,
and permeability of the visceral pleura. The net result would be pleural effusion with extravasation of
PMNs into the pleural space.

The recruitment of PMNs to the pleural space after trauma is an evolutionary response with
pathologic consequences in the perioperative setting. In contrast to surgical intervention, penetrating
trauma to the pleura (or lung) outside of a hospital is usually accompanied by inoculation with bacteria[50].
The normal physiologic immune response is to control infection after trauma[50]. PMNs function as
effectors by de-granulation; specifically, they release cytotoxic and histotoxic substances as a means of
bactericide[50]. This endogenous insult propagates serosal inflammation and a high degree of metabolic
activity by mesothelial cells[52, 53]. Loosening of tight and gap junctions along the vascular endothelium
potentiates the migration of circulating Mϕ cells into the pleural space. This increased permeability also
increases filtration of fluid into the pleural space. Once in the pleural space, PMNs do not return to the
blood stream[49]. These cells will undergo apoptosis and their remnants removed by Mϕ phagocytosis
over time[49]. In this framing, PMN degranulation and apoptosis become mediators for mesothelial
effector cells. Continuous stimulation of mesothelial cells and leukocyte migration likely potentiates the
maintenance of pleural effusion.

Cytological profiles for pleural fluid that are consistent with our inflammatory model have been
described for patients after cardiac surgery[37]. Sadikot, et al, have shown significant differences to exist
between pleural fluids evacuated from patients during early and late periods post CABG[37]. Early
effusions (<30 days) have greater levels of neutrophils versus late effusions (0.242 vs. 0.8 X 109/L), which
supports an early PMN response[37]. Late effusions have lymphocyte predominance (0.68 vs. 0.125 X
109/L, p<0.001). The later finding supports a humeral response[37, 49]. These clinical observations
suggest that there are both acute phase and humeral responses that involve the pleural space.

Page 20 of 67

The complete mechanism of resolution of pleural effusion after cardiac surgery is currently
unknown. The metabolic profiles of mesothelial cells during effusion suggest these cells play a role in
recruitment of circulating Mϕ cells[52, 53]. Recruited circulating Mϕ cells are typically responsible for
phagocytic removal for apoptotic PMNs (so called, efferocytosis); but this has not been fully elucidated for
the pleural space. Study of rat pleurisy models by Muria, et al, has suggested that PMNs have an extended
life in the pleural space and apoptotic activity begins very shortly after recruitment to the pleural space[49].
In small animal models of pleural injury, it has also been demonstrated that activated tissue Mϕ cells
migrate from the pleural space to regional lymph nodes to potentiate a humeral immune response[49].
Therefore, reducing stimulation of tissue Mϕ by leukocytes in the pleural space may reduce the persistence
of effusion and blunt the development of a humeral response.

Our interpretation of the literature is that the pathogenesis of non-specific pleural effusion after
cardiac surgery is interrelated lung and pleural acute phase inflammation that can evolve into a humeral
response. The presence of apoptotic neutrophils in the pleural space could be a propagating mechanism for
pleural inflammation and effusion. Prolonged pleural inflammation may also increase the likelihood a late
humeral response by an unknown mechanism. If this is the case, reducing PMN recruitment into the
pleural space, or removing apoptotic PMNs from the pleural space might shorten the duration of pleural
inflammation and effusion. Further, it might also blunt the development of a humeral response. Heidecker
and Sahn suggested that early [e.g. non-specific] and late pleural effusions were based on different
etiologies with different pathogenesis[54]. We speculate that an evolving inflammatory response might be
a better explanation.

3.6.3

Post-pericardiotomy Syndrome, Atrial Fibrillation and Pleural Effusion

Post-pericardiotomy syndrome (PPS) is a condition that affects 10-40% of patients after cardiac
surgery[55]. PPS is cited to be the result of a humeral inflammatory response with a poorly understood
pathogenesis[55, 56].

The syndrome is characterized by a specific constellation of symptoms at

approximately 1-6 weeks after any type of pleuro-pericardial trauma[55].

The generally accepted
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diagnostic criteria includes presentation with 2 of the following: 1) fever; 2) pleuritic chest pain; 3) rubs
(pericardial or pleural); 4) pericardial effusion; or 5) pleural effusion (with or without elevated CRP)[55,
57]. The progression of the syndrome is thought to start with an iatrogenic trigger (cardiac surgery) and
has a “sub-clinical” latency period until symptoms appear approximately 2-3 weeks later[55]. The “subclinical” latency period is often characterized by maintenance or development of a late pleural effusion[5].
Symptoms of PPS can be important because approximately 2-3% of symptomatic patients go on to develop
constrictive pericarditis[55, 56].

As such, these patients may require more vigilant follow up after

surgery[55, 56].

We are interested in the PPS for several reasons that are based on our understanding of pleural
effusion after cardiac surgery. First, it is estimated that up to 85% of patients with a diagnosis of PPS
present with a pericardial effusion but up to 90% will present with a pleural effusion[56]. Second, ontreatment analysis in the COPPS-2 randomized controlled trial showed that perioperative colchicine
reduces pericardial effusion and pleural effusion after cardiac surgery (relative risk reductions 44%, 52%
respectively)[57]. The mechanism of action for colchicine includes inhibition of TNF-α synthesis by
macrophages and down regulation of TNF-α-receptor expression on both macrophages and endothelial
cells[58]. Additionally, colchicine inhibits microtubule assembly in PMNs, which blunts mobilization[58].
Therefore, the expected effect would be reduction of tissue macrophage activation and PMN recruitment to
the pleural space. Considering our current model, we might have expected a reduction in pleural effusion
from this therapy. Unfortunately during the COPPS-2 trial, colchicine had to be discontinued in 22% of
patients due to gastrointestinal side effects[58].

Third, we are interested in the 45% reduction in postoperative atrial fibrillation (NNT=11) found
on on-treatment analysis from the COPPS-2 trial[57]. The authors did not comment on the covariance of
reduction in pleural effusion and atrial fibrillation. However, our Cardiac Surgery service has anecdotally
noted reductions in maintenance of atrial fibrillation with early thoracentesis on patients with postoperative
pleural effusions. The authors of the COPPS-2 trial indicated that there were two possible mechanisms for
reduction in postoperative AF in patients receiving colchicine[57]. These included reduction of calcium-
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induced ectopy by inhibition of microtubule assembly and by reduction of PMN recruitment to damaged
cardiac tissue[57].

Further, a retrospective multivariate analysis of 969 patients by Stamou, et al, found that
postoperative pleural effusion was an independent risk factor for atrial fibrillation (RR = 3.2, 95% CI 1.09.4, p=0.03)[59]. Pericardial effusion is also a known risk factor for AF and up to 63% of patients maintain
a sub-clinical pericardial effusion 1-week after surgery[60]. Vargas, et al, have previously demonstrated
that the persistence of pericardial effusion is dependent on the persistence of pleural effusion after
myocardial revascularization[61]. Perhaps this is explained by relationship between the lymphatic systems
for both the pericardium and pleurae[62]. The majority of the pericardium and left chest is drained through
the upper thoracic duct. This route has a high recruitable capacity for pleural drainage but recruitment may
impact the system’s capacity for pericardial drainage[23]. Mechanical compression activates pericardial
mesothelial cells (by effusion) and promotes pericardial inflammation[52]. If pericardial effusion is a risk
factor for AF and resolution of pericardial effusion is dependent on resolution of pleural effusion, it would
be reasonable to think that treating pleural effusion may have a downstream effect on resolution of AF.
Whether or not draining the pleural space has an impact on prevalence of postoperative AF is unknown.

3.7

Thoracentesis: A Role in Non-Specific Pleural Effusion?
The clinical considerations for use of thoracentesis in non-specific pleural effusion after cardiac

surgery should weigh risk of injury against the potential for benefit. Up until the past 10-15 years, the
historical safety profile of thoracentesis had been poor.

In 1993, a review by Bartter, et al of 337

thoracenteses performed without imaging guidance cited a major complication rate of 4-30%[63]. These
complications consisted primarily of pneumothorax but also included hemothorax, splenic laceration, and
even a retained surgical instrument[63].

The overall percentage of patients requiring intervention for

complications was 6%; and these included tube thoracostomy, blood transfusion, and thoracotomy[63].
There were also several deaths in critically ill patients requiring thoracentesis[63].
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However, the sensitivity and increasing adoption of thoracic ultrasound has dramatically changed
the safety profile of thoracentesis over the last decade. For cardiac surgery patients, this has been realized
in terms of both improved “real-time” detection of pleural effusions and reduced complications[64, 65]. In
a recent study by Usta, et al, 135 patients requiring thoracentesis had their procedures performed under
ultrasound guidance[65]. The resulting therapeutic yield was 100% [e.g. fluid was obtained from patients]
with a 0% complication rate[65]. The overall reduction in complications with thoracic ultrasound has led
our Cardiac Surgery service to reexamine the utility of thoracentesis in patients with non-specific pleural
effusion.

The generally accepted therapeutic mechanism for thoracentesis is the reduction of restricted
ventilation[11, 12]. Symptoms of restricted breathing tend to increase with the size of pleural effusion[11,
12].

However, symptoms of respiratory dysfunction are independent of size in non-specific pleural

effusion[3-6, 13]. These symptoms are clinically significant and negatively correlate with outcomes. In
the previously cited study by Usta, et al, thoracentesis was reserved for patients with a pre-procedure
pleural fluid volume estimate of >480mL[65]. Patients undergoing thoracentesis were discharged on POD
9–10, whereas patients with smaller effusions that were managed with diuretics stayed 3 ± 1.5 days
longer[65]. This suggests that patients with smaller pleural effusions might have had clinically significant
symptoms that led to longer hospital stay.

Clinical benefits for thoracentesis in patients with non-specific pleural effusion after cardiac surgery
have not been described. Based on the current literature, we can only speculate that patients with nonspecific pleural effusion might benefit from thoracentesis. Symptomatic improvement after thoracentesis is
generally correlated with increasing volume of pleural fluid removed[11, 12]. However, benefit in nonspecific pleural effusion would have to be realized from a different mechanism because the effusions are
small. Our interpretation of the current literature is that the pathogenesis of non-specific pleural effusion
after cardiac surgery is interrelated lung and pleural inflammation. The presence of apoptotic neutrophils
in the pleural space is a propagating mechanism for lung and pleural inflammation.

Symptoms of

respiratory dysfunction, including dyspnea, are a known consequence of lung and pleural
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inflammation[32]. Therefore, we can speculate that early reduction of PMN burden in the pleural space
with thoracentesis might shorten the duration of lung and pleural inflammation, as well as pleural effusion.
Thoracentesis might also result in fewer days in atrial fibrillation if treating a non-specific pleural effusion
is associated with resolution of sub-clinical pericardial effusion.

4

Study Design, Specific Aims, and Hypothesis

4.1

Statement of Purpose and Specific Aims
This study retrospectively compares clinical outcome measures for cardiac surgery patients with

non-specific postoperative pleural effusions, some of whom had procedural intervention with thoracentesis
and others that did not. The use thoracentesis in this setting is currently based on clinical judgment that
weighs established risk against poorly described benefit. Complications from thoracentesis performed by
our Thoracic Interventional Program Service (TIPS) under transthoracic ultrasound guidance are generally
regarded as infrequent and are beyond the scope of this study. Some cardiac surgeons assert that there is
benefit to early thoracentesis for non-specific pleural effusion in specific cases. However, the current
literature neither provides sufficient data on the frequency of improved dyspnea [e.g. clinical benefit] after
thoracentesis, nor formal comparisons of clinical outcomes to fully support expanded use in this
population. Better understanding of these outcomes to inform clinical judgment is emerging as a clinical
imperative at our institution.

The purpose of this study is to 1) measure the frequency of improved dyspnea after thoracentesis on
cardiac surgery patients with non-specific pleural effusion; and 2) compare clinical outcomes between
patients who had thoracentesis versus those who did not. The scope of clinical outcomes studied is
informed by the current literature but limited to the anecdotal clinical observations reported by mid-level
providers at Yale - New Haven Hospital. To our knowledge, this is the first comparative evaluation of
outcomes for “therapeutic” thoracentesis in cardiac surgery patients with non-specific pleural effusion.
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4.2

Study Design
A Case – Control design is chosen for this study. Cardiac surgery patients with postoperative

pleural effusion who had thoracentesis in the early postoperative period (Cases) are matched by age and
operation with patients who did not undergo thoracentesis (Controls).

We have chosen to match patients by age and operation for several reasons. First, surgical trauma
and CPB have been identified as risk factors for both developing and maintaining a pleural effusion
[Section 3.4]. If an outcomes comparison is to be made regarding postoperative pleural effusion, the extent
of surgical trauma and general use of CPB should be comparable. There is inconsistent evidence for time
on CPB as risk factor for postoperative pleural effusion and for this reason we consider this less
contributory[4, 25]. Second, the Cardiac Surgery team at Yale – New Haven Hospital acknowledges
differences in length of stay that is operation specific (e.g. CABG patients tend to have shorter lengths of
stay than CABG patients with concurrent AVR). Third, there is insufficient data to control for the potential
the modifying effects of specific operations on the development or persistence of AF in the postoperative
period. Therefore, matching by operations may provide a more meaningful comparison between cases and
controls. Fourth, age is a known risk factor for both length of stay and the development of AF[66].
Matching by age would attempt to eliminate this source of selection bias. Outcomes experienced by
patients are summarized and where appropriate, compared between Case and Control groups.

For this analysis, 30 patients were selected based on the Statistical Considerations outlined in
Section 5.7. Medical chart data is collected from documented outcomes observed, including a surrogate
measure of dyspnea, hospital length of stay (LOS), rate of escalation of care, days in atrial fibrillation,
markers of systemic inflammatory response, and requirement for further outpatient management of pleural
effusion after discharge. Data is collected from a population of patients after cardiac surgery by a single
surgeon to limit inter-operator variability and at a single institution to limit variability in postoperative care.

Observational end points are the subject of this study for several reasons: 1) Mid-level providers
reported their informal observations for patients that have already received care at our institution, 2) The
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clinical outcomes of interest are sufficiently well documented in the electronic medical record, 3) There is
currently a lack sufficient clinical data to reasonably justify a prospective study at this point; and 4)
Outcomes data can be used in further hypothesis refinement for potential prospective trials if warranted.

4.3

Hypothesis
We believe that the majority (>50%) of patients who undergo thoracentesis for non-specific pleural

effusion have improved dyspnea.

We will formally measure the frequency of improved dyspnea

experienced by these patients to support this assertion. In terms of comparative clinical outcomes, the null
hypothesis is that there is no difference between patients having thoracentesis versus no procedural
intervention for non-specific pleural effusion after cardiac surgery in terms of:

1) the frequency of

improved dyspnea, 2) LOS, 3) requirement for escalation of care, and 4) days of AF. The alternative
hypothesis is that thoracentesis improves these clinical outcomes.

Our argument for an alternative

hypothesis is based on: a) increased length of stay is associated with persistence of dyspnea and AF[65,
67], b) decline in pulmonary status is a common reason for escalation of care at our institution, and c) our
current model of inflammation for non-specific pleural effusion after cardiac surgery suggests that
persistence of effusion and days in AF might be reduced by removal of PMNs from the pleural space.

4.4

Study Endpoints
Primary Endpoint: What is the frequency of improved dyspnea after thoracentesis for non-specific

pleural effusion after cardiac surgery?
Secondary Endpoint: Is there a difference in postoperative length of stay for patients who had
thoracentesis versus those who did not?
Tertiary Endpoint:

What are the rates of escalation of care for patients who underwent

thoracentesis and those who did not?
Additional Endpoints: Is thoracentesis associated with fewer postoperative days in AF in cardiac
surgery patients? Was the medical management of AF with amiodarone in Controls and Controls different?
Is there a difference in incidence of post-pericardiotomy syndrome? What is the requirement for postdischarge care of pleural effusions in those who had early thoracentesis and those who did not? What was
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the average hospital length of stay from intervention (thoracentesis) to discharge? What was the 30-day
mortality? What was the absolute mortality? What amount of fluid is removed from patients requiring
thoracentesis? Were there markers of systemic inflammation during the postoperative period for Cases or
Controls?

4.5

IRB Review and Approval
This medical record review was conducted according to the current revision of the Declaration of

Helsinki. The Institutional Review Board at Yale University approved the clinical study protocol prior to
study initiation on December 14th, 2014 as HIC #1412015043.
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5

Methods

5.1

Roles and Responsibilities
This project is the culmination of efforts by many individuals. A detailed list study contributors is

shown below (Table 1). The medical student (David R. Kull, MPH) role was limited to the following
work: Coordination of Research Team Contributions, Primary Authorship and Revision of Study Protocol,
Case-Control Selection, Abstraction of Clinical Outcomes Data (All Records), Statistical Analysis of
Outcomes Data, and Primary Authorship of Manuscript. The medical student did not participate in the
following activities or responsibilities: Principal Investigator, Expert Review of Study Protocol, Expert
Review of Manuscript, Draft or Submission of HIC Documentation (based on Study Protocol).

Table 1: Key Study Personnel
Principal Investigator:
Umer M. Darr, MD
Department of Surgery, Section of Cardiac Surgery
Role: Principal Investigator, Protocol Review,
Manuscript Review
Co-Investigator:
Gaetane C. Michaud, MD
Dept. of Medicine, Section of Pulm. and Crit. Care
Role(s): Protocol Review, Manuscript Review

Co-Investigator:
David Kull, MPH (Medical Student)
Yale University School of Medicine
Role(s): Author Protocol, Case/Control Selection,
Records Abstraction, Data Analysis, Author
Manuscript
Co-Investigator:
Jonathan T. Puchalski, MD
Dept. of Medicine, Section of Pulm. and Crit. Care
Role(s): Clinical Contributor

Co-Investigator:
Christina Carbone, CCRP (Research Coordinator)
Dept. of Medicine, Section of Pulm. and Crit. Care
Role(s): HIC Application Draft and Coordination,
Protocol Review

Co-Investigator:
Barbara Stahl, APRN, DNSc (Acute Care NP)
Department of Surgery, Section of Cardiac
Surgery
Role(s): Protocol Review

Co-Investigator:
Vladimir Shumaster, MD (Research Fellow)
Department of Surgery, Section of Cardiac Surgery
Role(s): Protocol Review

Co-Investigator:
Kelsey Johnson, MSc, PA-C (Clinical PA)
Department Surgery, Thoracic Interventional
Program
Role(s): Protocol Review
Study Personnel:
Ann Roselle, MS, PA-C (Clinical PA)
Department of Surgery, Section of Cardiac
Surgery
Role(s): Protocol Review
Thesis Sponsor:
Frank Detterbeck, MD
Department of Surgery, Section of Thoracic
Surgery
Role(s): Thesis Review

Study Personnel:
Rowena Saga-Abrina, APRN (Clinical NP)
Department of Surgery, Section of Cardiac Surgery
Role(s): Protocol Review
Study Personnel:
Eileen Taylor, RN, MBA
Department of Surgery, Section of Cardiac Surgery
Role(s): Protocol Review
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5.2

Study Population
Patients who are status-post cardiac surgery, performed by a single surgeon (Umer M. Darr, MD) at

Yale - New Haven Hospital during the two-year period commencing January 1st, 2013 and ending
December 30th, 2014, with a radiographically evident pleural effusion were considered. Cases and Controls
were selected amongst patients meeting Inclusion and Exclusion Criteria (described in Sections 5.2.1 and
5.2.2 respectively) by the procedure defined in Section 5.3. In brief, the Case group is comprised of
patients meeting inclusion and exclusion criteria in which thoracentesis was performed during the early
postoperative period. The Control group is selected amongst age and operation matched patients, who did
not undergo early thoracentesis during the same period.
5.2.1

Inclusion Criteria

Subjects must meet all of the following inclusion criteria to be entered into the study:
1.

Post-primary open cardiac surgery (CABG, valve, CABG + valve, etc.)

2.

Age 40-85 years

3.

Postoperative pleural effusion in the early postoperative period (POD3 - POD7)

5.2.2

Exclusion Criteria

Any of the following will exclude the subject from study:
1.

Prior cardiac surgery

2.

History of pleurodesis

3.

Patients with pleural effusion known to be associated with non-cardiac related etiology (e.g.
pancreatitis, malignancy, etc.)

4.

Operative complications (intraoperative bleeding requiring massive transfusion protocol or
documented inadvertent intraoperative injury)

5.

Maintenance of a chest tube or tunneled pleural catheter during the early postoperative period

6.

INR > 2.5 (for Cases, at the POD of thoracentesis; Controls, the matched POD)

Rationale for exclusion criteria: The primary endpoint of the study is to formally measure the frequency of
reduced dyspnea after cardiac surgery, whereby an inflammatory response is considered an underlying
mechanism. Intra-thoracic fibrosis from prior surgery may complicate the course of non-specific pleural
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effusion (e.g. formation of loculations). Pleurodesis causes fibrosis within the thoracic cavity and may
change the course of non-specific pleural effusion[53]. Micro-metastatic malignancy is thought to cause
pleural effusion by a separate process that may promote persistence of pleural effusion[24].

Major

operative complications, defined as intraoperative bleeding requiring massive transfusion protocol and
documented injury of intra-thoracic structures, may provoke an immune response beyond that experienced
by most cardiac surgery patients. Additionally, we can reasonably assume this would impact length of stay
and requirement for escalation of care. Maintenance of an indwelling tunneled pleural catheter has been
associated with spontaneous pleurodesis[68]. Intraoperative insertion of a chest tube to drain the left
pleural space has also been shown to reduce pleural effusion after cardiac surgery[69]. INR >2.5 is a
reference value at the upper standard deviation of increased risk for the development of hemothorax
requiring transfusion after thoracentesis[70]. From our current interpretation of the literature subclinical,
bleeding might prolong pleural inflammation and effusion.

5.3

Selection of Cases and Controls
Query of electronic medical records resulted in a Primary Search Group (PSG) of 377 records for

consideration amongst patients of Umer M. Darr, MD at Yale - New Haven Hospital during the two-year
period commencing January 1st, 2013 and ending December 30th, 2014. Within the PSG, 58 patients had
undergone thoracentesis. Manual search of these records yielded 34 patients having had thoracentesis
during the period of interest (POD3-7). Of these, 21 patients met the remaining inclusion criteria. Of those
meeting inclusion criteria, 4 patients met exclusion criteria on further review due to non-cardiac etiology of
a chronic pleural effusion (3) or prior sternotomy(1). The 17 remaining patients were assigned to the
preliminary Case Group.

Re-generation of the PSG excluding the 58 patients found to have undergone thoracentesis during
the perioperative period produced 319 patients. 84 patients were identified as age matched by list sort.
Through manual search, 19 procedure matches were identified amongst matched ages. These records were
assigned to the preliminary Control Group.
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There were 2 additional patients meeting criteria for Cases and 4 additional patients meeting criteria
to match as Controls to 4 of the first 15 Cases selected. The 2 additional preliminary Cases were not
assigned because there was no ability to appropriately age and/or procedure match amongst the available
Controls. There were 4 additional Controls that could have been matched to Cases. We selected those that
were closest in age as this would be the most reliable comparison. The Case and Control groups were then
finalized with the best matches available. A schematic for Case and Control Selection by numbered step is
shown in Figure 1.

5.4

Data Abstraction
Data abstraction was performed by manual search by a medical student and is documented using the

Data Abstraction Form attached as Appendix A. Data abstracted was handled per the Data Management
procedure listed in Section 5.5.
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Figure 1: Case and Control Selection
Primary Search Group:
Umer Darr, MD
Cardiac Surgery Cases at YNHH
Jan. 2013 – Dec. 2014 (377)

1

Thoracentesis (58)

Non Inclusion or
Excluded (186)

Non Inclusion by
POD3-7 Thoracentesis
(24)

2

Thoracentesis
POD3-7 (34)
Not Included by Other
Criteria or Excluded
(17)

3

Preliminary Cases
(17)

Legend:
Procedure Step Number

Control Pool
Age Matches
+/- 3 Years (84)

4

Not Age
Matching (49)

5

No Procedure
Matching (65)

6

Preliminary
Controls:
Age and Procedure
Matched (19)

Best Matching by Procedure
and Closest Age

7

#

Preliminary
Control Pool (319)

Cases:
Thoracentesis POD3-7
(15)

Controls:
No Thoracentesis
POD3-7
(15)

Figure 1: Cases and Control selection; 377 patients considered; 58 patients were to found to have undergone
thoracentesis for non-specific pleural effusion; 41 preliminary Cases were removed by inclusion/exclusion criteria. 2
preliminary cases were unmatched. Of 319 potential controls, 84 were age matched and 19 were procedure matched.
Matching by closest age yielded 15 Cases and 15 Controls

5.4.1

Specific Data Elements

Data elements are retrospectively abstracted from patient charts for the following:
•

•

Baseline Data
o

Age

o

Cardiac surgical procedure

Cardiopulmonary Recovery
o

Daily Peak Supplemental O2 Requirement (LPM), POD3 to discharge (or POD7)

o

Daily Occurrence of AF POD3 to discharge (or POD7)

o

Cumulative dose requirement for amiodarone POD3 to discharge (or POD7)

o

Number of days with fever (e.g. T > 38.3° C) POD3 to discharge (or POD7)

o

Labs: Daily WBC and Platelets (POD3 - POD7, or last lab draw)

o

POD of thoracentesis (Cases)
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o

Postoperative Course

•

o

Length of post-operative inpatient stay (LOS)

o

Requirement for escalation of care (e.g. Step-down or CTICU re-admission)

Post-discharge Course

•

5.5

Pleural fluid volume removed (Cases)

o

Diagnosis of post-pericardiotomy syndrome

o

Death (< 30-days)

o

Requirement for hospital re-admission

o

Requirement for outpatient management of pleural effusion

Data Management
The study is exclusively conducted at Yale University School of Medicine through Yale - New

Haven Hospital. Hard copy, de-identified Case Report Forms are used to collect data are secured under
lock-and-key in a binder within the Section of Cardiac Surgery on completion of Data Abstraction. All
electronic media is held in accordance with IRB policies and procedures. Additionally, de-identified data is
periodically loaded into Microsoft Excel® and STATA (STATA LP, College Station, TX, USA) for
analysis and safeguarded on an encrypted hard drive per IRB policies and procedures. All data records
used for the study, paper and electronic, will be destroyed on or before a period of 5 years (12/31/2019).

5.6

Data Analysis
The primary endpoint of this study is frequency of improved dyspnea as measured by daily peak

supplemental O2 requirement before and after thoracentesis. The generally accepted criteria for therapeutic
thoracentesis in our patient population includes symptoms[5]. We have chosen peak supplemental O2
requirement as a measure of dyspnea for several reasons. At Yale – New Haven Hospital, the order for
titration of oxygen supplementation is nursing-driven and is given as:
Nasal Oxygen Titration (Adult)
•

[Timing], [Duration], [Start Date, Time], [End Date, Time]

•

Starting Liter Flow (LPM): 2.0 LPM
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•

SpO2 Goal: > or = 92%

•

Indications: Treat/Prevent Hypoxemia

•

Flow Range: [Flow Range]

•

Titrate Flow: [Titration Flow]

•

Notify MD/LIP: [Any Specific Notification Instructions]

The translated action by nursing staff is most often to supplement oxygen to “prevent hypoxemia.”
Further, an acceptable interpretation of these orders often results in nurses adding 2L of oxygen for what
they deem as, “patient comfort.” This commonly occurs when SpO2 is above 92% to prevent hypoxemia
in the setting of early increased work of breathing. The initial flow typically given is also in accordance
with physician orders, which is 2 LPM. Oxygen is titrated up based on a combination of increased work of
breathing and trending of hypoxia by SpO2. The peak oxygen supplementation that is the end result of
titration is probably a good measure of exactly how much dyspnea someone is experiencing prior to
changes in supplementation.

Does everyone get 2 LPM of oxygen when they’re experiencing some increased work of breathing?
This is also probably not the case. The subjectivity of a nurses’ assessment of increased work of breathing
may be influenced by, among factors, recent thoracentesis. If a thoracentesis has been performed, there
might be an expectation that someone will get better. This could be an influence for a nurse to titrate less
aggressively if there is a subjective expectation. The measure of SpO2 has been used in prior studies to
measure hypoxia in patients before and after thoracentesis[65].

We considered using this measure,

however, many patients requiring cardiac surgery have chronic obstructive pulmonary disease.

It is

common for these patients to have a low baseline SpO2 without significant changes in baseline work of
breathing. If a patient’s work of breathing isn’t dramatically changed, this may result in less aggressive
initiation of oxygen supplementation by nurses if the SpO2 is > 92%. Lastly, it is rare at our institution for
someone to have an SpO2 < 92% at the time of surgeon orders for thoracentesis. This result is primarily a
function of the physician order set for oxygen titration. For these considerations, we are choosing to use
daily peak O2 supplementation as a measure of dyspnea. Further, we think that a relevant measurable
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difference is 2 LPM because the oxygen titration starts at a 2 LPM by our order set. Although this has
never been measured and is not dictated by the order set, our practitioners report that most patients are
titrated off oxygen from 2 LPM. We would therefore consider “improved dyspnea” by a reduction of 2
LPM.

We feel POD3 - POD7 is a reasonable inpatient study period for several reasons. Patients at our
institution are admitted to the CT-ICU following open cardiac surgery. On approximately POD 1-3,
patients’ chest tubes are typically removed and they are transferred to the CT-SDU. Following 24-48 hours
in CT-SDU, patients are transferred to the Cardiovascular Medical Floor (CMF) where they typically
remain until discharge.

Thoracentesis for non-specific pleural effusion occurs after chest tubes are

removed (usually POD2). The literature suggests that non-specific pleural effusions resolve within 1 week
of surgery (POD7)[5]. Therefore, we choose these as the limits of data to examine.

The secondary endpoint is hospital length of stay (LOS); which is defined as period of time
commencing with the day of the primary operation and ending the day of discharge. A mean difference in
hospital stay for patients of at least 1 day is considered meaningful because inpatient hospital stay is
recorded by the day in our EMR. Patients are recorded as discharged based on the date of the hospital
discharge summary. Therefore, there is no difference recorded if a patient is discharged before or after
11:00 AM (the official time of discharge set by hospital administration for billing purposes). Mid-level
practitioners estimate that the average hospital LOS for patient at our institution is typically 5-6 days,
although this has not been formally measured. The literature suggests that patients with symptomatic
pleural effusion after cardiac surgery stay 9-10 days after thoracentesis, and 12-13 days if diuretics are used
as an intervention[65].

The tertiary endpoint is requirement for escalation of care. This is defined as the physical relocation
of a patient to another Unit where the intensity of care is higher due to clinical need. Our Cardiac Surgery
service accepts a rate of escalation of care of ≤10%. In the rare case that a patient is not transferred from
the CT-SDU to the CMF due to bed management issues, and documentation of an adverse change in
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clinical course is present in the patient Discharge Summary, the patient were recorded a having had an
escalation of care.

Additional outcome endpoints include days of documented atrial fibrillation; a requirement for
outpatient thoracentesis for pleural effusion after discharge; evidence of systemic inflammation [e.g. WBC,
Fever, platelets]; incidence of post-pericardiotomy syndrome; average hospital length of stay from
intervention to discharge; amount of pleural fluid removed during thoracentesis; 30-day and absolute
mortality.

Statistical analysis of study data is accomplished in STATA/IC 10.1 (Stata Corporation, 4905
Lakeway Dr., College Station, TX 77845 USA) using the Do-Command Program, written by the medical
student (David R. Kull, MPH) and attached hereto as Appendix B.

5.7

Statistical Considerations
The primary endpoint of this study is frequency of improved dyspnea as measured by daily peak

supplemental O2 requirement before and after thoracentesis. Our study objectives are to review enough
patient records sufficient to provide for both the statistical power required to be reasonably confident in the
measurement of our primary and tertiary endpoints. Additionally, we would like to detect meaningful
differences between Case and Control groups for the secondary endpoints. We will not purposefully power
the study to detect differences in other endpoints.

A sample size of 30 (n) is chosen (Cases=15, Controls=15) based on the following considerations:
Primary Endpoint: The primary endpoint of this study is frequency of improved dyspnea. This
is defined by a reduction in daily peak O2 supplementation of 2 LPM after thoracentesis. We
conservatively estimate that the majority of patients (>50%) have improved dyspnea after
thoracentesis. In order to be reasonably confident in our actual rate being above 50%, we would
need to observe rates that differ by the number of patients:
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Observed Rate (%)
60
70
80
90
70
80

Actual Rate (%)
50
50
50
50
50
50

Confidence (%)
95
95
95
95
90
90

Patients (n)
152
36
15
7
26
11

Statistical estimates can be made for the magnitude of difference in means for daily peak O2
supplementation before and after thoracentesis. We estimate that the average thoracentesis patient
in our population requires daily peak O2 supplementation of about 4 LPM (+/- 2 LPM) to maintain
SpO2 above 92%, although this has not been formally measured. A minimum post-thoracentesis
value would be 2 LPM (+/-2) based on our definition of “improved dyspnea.” To detect this
difference where α = 0.05 and β = 0.20, a minimum of 12 patient records must be analyzed (n=12).

We expect that patients who do not have thoracentesis will also have improved dyspnea, as nonspecific pleural effusion is known to resolve spontaneously[5]. The perioperative day-to-day
course of spontaneous dyspnea improvement [e.g. when and how much] in this population has not
been described.

We believe that the majority of patients will have improved dyspnea after

thoracentesis independent of the POD of intervention. However, the proportion of patients with
spontaneous improvement is presumed to be higher in the early versus later perioperative course
[e.g. POD dependent]. Therefore, we will measure and compare differences in improvement of
dyspnea for Cases and Controls but we do not yet have enough information to formally power the
study to detect these differences.

Secondary Endpoint: Our secondary endpoint is hospital length of stay measured in days. The
average hospital stay for patients following cardiac surgery is approximately 5 days (+/- 1-day). A
mean difference in hospital stay for patients of at least 1 day is considered meaningful because
inpatient hospital stay is typically recorded and billed by the day. The mean hospital length of stay
will be calculated based on collected data and a paired t-test will be performed. Assuming that the
average length of stay is 5 days with a standard deviation of 1 day, and an average mean difference
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in length of stay is 4 days with a standard deviation of 1 day where α = 0.05 and β = 0.20, a
minimum of 12 patient records per group must be analyzed (n=24).

Tertiary Endpoint: The tertiary endpoint of our study is requirement for escalation of care as
measured by physical transfer to a unit where the intensity of care is higher. We have units for
three levels of care at Yale New Haven Hospital [e.g. Cardiovascular Medical Floor,
Cardiothoracic Step Down, and CTICU] and therefore our definitions and thresholds for transfer
may be specific to our institution. Estimates of escalation of care available in the current literature
are therefore difficult to generalize for our institution. However, the rate of escalation of care for
postoperative cardiac surgery patients ranges from approximately 4-13% based on hemodynamic
instability and the rate of iatrogenic injury from thoracentesis requiring intervention is between 06%[63, 67]. At our institution, a clinically acceptable rate of escalation of care will be defined as
≤10%. The rate of escalation of care in our population has not yet been defined. No comparison
will be made for escalation of care between Cases and Controls. However, the rates of escalation
of care will be calculated for each group and confidence intervals will be calculated using
Newcombe’s interval (with continuity correction). The Probability (P) of observing the rates of
complications for our analysis based on an acceptable comparison rate of ≤10% (p) will be
calculated by binomial expansion. We accept that at one patient in ten will have required an
escalation of care. To be 80% confident (P) that our rate is ≤10%, the observed rate in our study
must be 7% per group. A sample size of 15 per group (n=30) will allow us to detect an observed
rate of 7% [e.g. 1 event amongst 15 patients] with 80% confidence that our actual rate is ≤10%.

The minimum sample size for our study is n=30 (15 Cases, 15 Controls), which is driven by two
requirements. First, we would like higher confidence in our primary endpoint because the estimation of our
actual rate is conservatively low (>50%). Our mid-level providers assert that our recent rate of improved
dyspnea is 90-100%. We think that a 15-patient Case group provides us with sufficient patients for 95%
confidence if our observed rate is 80%. The second requirement is reasonable confidence (80%) in our rate
of escalation of care being ≤10%. We think that 80% confidence is reasonable given that this is a pilot
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study and this rate has never been measured. The sample sizes required for the primary and secondary
endpoints are lower based on the best available estimates of absolute differences expected between Cases
and Controls.
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6

Results

6.1

Baseline Patient Characteristics
Of patients studied, 20 underwent CABG, 6 underwent aortic valve repair (AVR), and 4 underwent

CABG with AVR as shown in Table 2. The mean age of the Case group was 75.3 years (SD = 8.2) versus
74.9 years (SD = 8.1); (p = 0.89).

6.2

Primary Endpoint: Frequency of Improved Dyspnea
The primary endpoint of this study is frequency of improved dyspnea as measured by daily peak

supplemental O2 requirement before and after thoracentesis. All patients maintained a pleural effusion on
POD3 during the study period irrespective of Case or Control status. Of 15 Cases, 11 had decreased peak
supplemental oxygen requirement ≥2 LPM the day after thoracentesis (RR=0.73, 95% CI 0.45 – 0.92). Of
the remaining Case patients, 2 patients had no change in dyspnea and 2 had worsening of dyspnea (≥2 LPM
increase). Additionally, 7 of 15 matched Control patients also experienced improved dyspnea over the
equivalent postoperative period. We did not detect a significant difference in the odds of improved dyspnea
between Cases and matched Controls (OR = 3.1, p = 0.14, 95% CI 0.7 – 14.5) or any other change in
dyspnea (p = 0.79). These results are shown in Table 2.

The day of thoracentesis ranged from POD3-POD5. The frequency of thoracentesis on POD3, 4,
and 5 was respectively 5, 6, and 4. Mean daily peak supplemental O2 requirement the day following
thoracentesis for Cases was significantly lower than the day before thoracentesis (1.7 versus 3.3 LPM, p =
0.01). The mean daily peak O2 requirement during the equivalent period for matched Controls was also
significantly lower over the same period (0.4 versus 1.7 LPM, p = 0.01). There was no relationship
between the volumes of pleural fluid removed and improved dyspnea by logistic regression analysis (p =
0.59).
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Figure 2: Postoperative Changes in Dyspnea Amongst Cases and Controls
A

B

Figure 2: A. Primary Endpoint: Frequency of improved dyspnea in cardiac surgery patients with non-specific pleural
effusion after thoracentesis (Cases) or a matched period (Controls), as measured by ≥2 LPM reduction in daily peak O2
supplementation. Of 15 Cases, 11 patients had improvement in dyspnea, and of 15 Controls, 7 patients had improvement.
There was no significant difference in the odds of improved dyspnea between Cases and matched Controls (OR = 3.1, p =
0.14). B. Daily peak O2 requirement was significantly lower for Cases after thoracentesis (1.7 versus 3.3 LPM, p =
0.01). The difference was also significantly lower over the same period for Controls (0.4 versus 3.7 LPM, p = 0.01).**
** Significance determined by paired t-test; which is independent of 95% confidence interval overlap in Figure 2B.

6.3

Secondary Endpoint: Postoperative Length of Stay
Study patients accounted for 188 days of postoperative hospital stay. The total postoperative days

experienced by cardiac surgery patients who had thoracentesis for non-specific pleural effusion were 101
days versus 87 days by those who did not have procedural intervention. The mean postoperative LOS for
Cases was 6.7 ± 3.2 days (median = 6) versus 5.8 days ± 1.6 days (median = 5) for Controls (p=0.84). The
mean length of stay from intervention to discharge for Cases was 2.8 ± 2.7 days and was not significantly
different versus the equivalent Control day to discharge, 1.9 ± 1.8 days (p = 0.84). Regression analysis
revealed a significant relationship between the volumes of pleural fluid removed during thoracentesis and
length of stay (Coef = 90 mL/day, p = 0.03).
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Figure 3: Postoperative Length of Stay Amongst Cases and Controls

A

B

Figure 3: A. Secondary Endpoint: The postoperative LOS for cardiac surgery patients who had
thoracentesis was 6.7 days ± 3.2 (median = 6) versus 5.8 days ± 1.6 (median = 5) for those with nonspecific pleural effusion who did have procedural intervention (p=0.84). B. Larger requirement for pleural
fluid removal significantly correlated with Case length of stay (Coef = 90 mL/day, p = 0.03).

6.4

Tertiary Endpoint: Requirement for Escalation of Care
During this study, there was no requirement for escalation of care documented amongst cardiac

surgery patients with non-specific pleural effusion. The 95% confidence interval for the rate of escalation
of care is 0% –14% based on an observed rate of 0% in 15 patient groups.
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Table 2: Comparison of Cases and Controls: Major Study Endpoints
Cases

Controls

n = 15

n = 15

Mean (SD)

Mean (SD)

(p)

75. 3 (8.2)

74.9 (8.1)

0.89

CABG

10

10

Aortic Valve Repair (AVR)

3

3

CABG + AVR

2

2

95% CI

Baseline Data
Age

Age

Procedure

Dyspnea
Improved

11

7

No Change

2

7

Worsened
Pre-/Post- Thoracentesis (or
matched period) Difference
for Daily Peak O2
Requirement (LPM)
Median Pleural Fluid
Drained
Postoperative LOS

2

1

-3.2¥ (4.6)

-2.3¥ (4.2)

Total Days
Average Days
Thoracentesis (or
Matched POD) to
Discharge
Requirement for Escalation of Care
Req. Esc. Care

0.14

0.36

-3.6 – 2.6

0.5 L
101

87

6.7 (3.2)

5.8 (1.6)

0.84

2.8 (2.7)

1.9 (1.8)

0.84

0

0

0.00 - 0.14*

Table 2: Comparison of Cases who underwent thoracentesis versus age and procedure matched Controls who had no
procedural intervention for non-specific pleural effusion after cardiac surgery. Age was not significantly different between
Cases and Controls (75.3 vs. 74.9 years, p=0.89). There is no significant difference for improvement of dyspnea between
Cases and Controls (11 vs. 7 patients, OR = 3.1, p = 0.14). Length of stay (LOS) was not significantly different between Case
and Control Groups (6.7 vs. 3.2 d, p = 0.84). LOS after thoracentesis (or matched POD) was also not significantly different
between Cases and Controls. There was no requirement for escalation of care in either group (95% CI 0.00 – 0.14).
¥
*

Reported as difference in means, consistent with the appropriate paired t-test. This is not as group mean
Confidence interval is estimated for actual rate of escalation of care, based on an observed rate of 0% in 15 patient groups.

6.5

Other Endpoints
6.5.1

Requirement for Post-Discharge Care of Pleural Effusion

The requirement for post-discharge outpatient management of pleural effusion was equal, 7% for
Cases who had thoracentesis and 7% for Controls who did not have procedural intervention (95% CI 0.000.34). The requirement for readmission was equal, 13% for both Cases and Controls (95% CI 0.02-0.42).
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6.5.2

Incidence of Atrial Fibrillation

A total of 11 patients with pleural effusion experienced at least one postoperative day of AF
following cardiac surgery from POD3-POD7 (RR = 0.37, 95% CI 0.21 – 0.56). There was no significant
difference between Cases and Controls for the incidence of postoperative AF (3 versus 8 patients, OR =
0.22, p = 0.13). Cases experienced postoperative AF for a mean of 2.3 days (SD = 1.5) and Controls
experienced a mean of 1.8 days, (SD = 0.7) (p=0.45) as shown in Table 3. Where thoracentesis was
performed before POD5 (n = 11), there was no incidence of AF in Case patients. This was significantly
lower compared to 6 of 11 Control patients who experienced AF as shown in Table 4 (p = 0.01).

There was no significant difference in the mean daily dose of amiodarone between Cases and
Controls during postoperative stay, 670 ± 1070 mg versus 730 ± 1070 mg, (p = 0.43). Cases required
significantly less amiodarone than Controls if thoracentesis was performed before POD5 (n = 10), 220mg ±
520 versus 930mg ± 1190, (p=0.01). Postoperative AF had resolved by discharge for Cases, however, 1
Control patient was in AF on the day of discharge.

6.5.3

Incidence of Post-pericardiotomy Syndrome

During this study, there was no incidence of post-pericardiotomy syndrome documented amongst
cardiac surgery patients with non-specific pleural effusion.

6.5.4

Evidence for Systemic Inflammation

During the inpatient study period, there was no significant difference in daily WBC for cardiac
surgery patients who had thoracentesis for pleural effusion versus who did not have procedural
intervention. Mean WBC during the inpatient study period was 9.8 ± 0.7 for Cases versus 9.9 ± 0.9 for
Controls (p = 0.46). Mean WBC the day after thoracenteses was 7.1 ± 5.1 for Cases versus 7.2 ± 5.4 X 103
cells/mL for Controls on the equivalent POD (p=0.48). There were no fevers reported for Case or Controls
during the study. The mean platelet count the day after thoracentesis was 139 ± 94 for Case and 151 ± 108
X 103 cells/mL for Controls on the equivalent POD (p = 0.37).
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6.5.5

30-day Mortality

There was neither 30-day mortality nor absolute mortality documented amongst cardiac surgery
patients with non-specific pleural effusion during this study.

6.5.6

Pleural Fluid Volumes Evacuated (Cases)

The median volume of pleural fluid removed from Case patients was 0.50 ± 0.50 L (Range 0.08 –
1.96L)
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Table 3: Comparison of Cases and Controls: Incidence of Atrial Fibrillation
Cases

Controls

n = 15

n = 15

Mean (SD)

Mean (SD)

(p)

3

8

0.13#

2.3 (1.5)

1.8 (0.7)

0.45

670 (1070)

730 (1070)

0.43

0

1

0.32

0

6

0.01#

220 (520)

930 (1190)

0.01

Mean
Day after
Thoracentesis
(or Matched POD)

9.8 (0.7)

9.9 (0.9)

0.46

7.1 (5.1)

7.2 (5.2)

0.48

Days (T > 38.3°C)
Mean on Day after
Thoracentesis (or
Matched POD)

0

0

0.5

139 (94)

151 (108)

0.37

30-day

0

0

Absolute

0

0

95% CI

Atrial Fibrillation (AF)
Total Patients with AF
Mean Days AF
Cum. Dose
Amiodarone
Patients Discharged in
AF
Sensitivity Analysis by POD
AF in Patients where
Thoracentesis < POD5 (n = 11)
Cum. Dose
	
  	
  
Amiodarone
Evidence of Systemic Inflammation
WBC

Fever
Platelets
Mortality

	
  	
  

0.00 - 0.14*
0.00 - 0.14*

Table 3: Comparison of Cases who underwent thoracentesis versus age and procedure matched Controls who had no procedural
intervention for non-specific pleural effusion after cardiac surgery. There was no significant difference in the study incidence of AF
between Cases and Controls (3 vs. 8 patients, p = 0.13). The mean number of days in AF for individual patients was approximately
2 days and was not significantly different between groups (p = 0.45). Cases who underwent thoracentesis earlier than POD5 (n =
10) had no postoperative atrial fibrillation. This was significantly lower compared to 6 Control patients who had AF (p = 0.01). The
cumulative dosing of amiodarone was significantly lower in Case patients when thoracentesis was performed <POD5 (n = 10, 220
vs. 930 mg, p = 0.01). There were no significant differences in markers of systemic inflammation including WBC (p = 0.46), fever
(p = 0.5), or platelet counts (p = 0.37). No patients died during the inpatient or outpatient study periods in this study. The estimated
95% CI based on the study observation of death is 0 –14%.
#
*

Determined by two – tailed Fisher’s Exact Test
Confidence interval is estimated for actual rate of mortality, based on an observed rate of 0% in 15 patient groups.
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Table 4: Postoperative AF and Day of Thoracentesis: Comparison of Cases and Controls

Controls

Cases

Postoperative Day (POD)
POD of
Thoracentesis
3
3
3
3
3
4
4
4
4
4
4
5
5
5
5
POD3-4 Match
POD3-4 Match
POD3-4 Match
POD3-4 Match
POD3-4 Match
POD3-4 Match
POD3-4 Match
POD3-4 Match
POD3-4 Match
POD3-4 Match
POD3-4 Match
POD5 Match
POD5 Match
POD5 Match
POD5 Match

Age
84
77
85
69
62
74
79
83
66
75
80
84
60
81
71
81
85
80
69
84
76
75
79
66
62
75
80
70
59
83

Operation
CABG
CABG
CABG
CABG
CABG
AVR
CABG
AVR
CABG
CABG
CABG+AVR
AVR
CABG
CABG + AVR
CABG
CABG
CABG
CABG
CABG
AVR
CABG
AVR
CABG+AVR
CABG
CABG
CABG
CABG + AVR
CABG
CABG
AVR

POD3

POD4

POD5

POD6

POD7

Legend
Day without AF
Day with AF
Discharged

Table 4: Comparison of Cases who underwent thoracentesis versus age and procedure matched Controls who had no procedural
intervention for non-specific pleural effusion after cardiac surgery. Amongst Cases and Controls, there was no difference in the
overall number of days of AF (2.3 ± 1.5 vs. 1.8 ± 0.7, p=0.45), or daily incidence of AF (OR = 0.22, p = 0.13). Where
thoracentesis was performed before POD5 (n = 10), there was no incidence of AF in Case patients versus 6 of 10 Control patients
(OR = 0, p = 0.01). There was no significant difference in the mean daily dose of amiodarone between Cases and Controls during
postoperative stay, 670 ± 1070 mg versus 730 ± 1070 mg, (p = 0.43).
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7

Discussion
Non-specific pleural effusion contributes to pulmonary dysfunction after cardiac surgery[4, 8-10].

In the present study, our objectives were to 1) measure the frequency of reduced dyspnea after thoracentesis
on cardiac surgery patients with non-specific pleural effusion; and 2) compare clinical outcomes between
patients who had thoracentesis versus those who did not have procedural intervention. To our knowledge,
this is the first comparative evaluation of outcomes for early thoracentesis in cardiac surgery patients with
non-specific pleural effusion.

The observed frequency of improved dyspnea after thoracentesis was 73% as measured by a ≥2
LPM reduction in daily peak supplemental O2 requirement. Although the limited sample size does not
allow this rate to be defined precisely, we are reasonably confident that the majority of patients improve
after intervention is performed (95% CI 0.45 – 0.92). The median volume of pleural fluid removed from
Case patients was 0.50 ± 0.50 L (Range 0.08 – 1.96L). There was no relationship between the volumes of
pleural fluid removed and improved dyspnea in our study (p = 0.59). The median pleural fluid volume
removed from patients by thoracentesis in our study generally correlates with blunting of the costophrenic
angles on a chest radiograph[65]. This volume is also at the intervention cut off point in the algorithm
proposed by Usta, et al for symptomatic patients[65].

We have proposed that non-specific pleural effusion after cardiac surgery is the result of interrelated
lung and pleural inflammation; and early reduction of PMN burden in the pleural space with thoracentesis
might shorten the duration of symptoms. Most non-specific pleural effusions are thought to spontaneously
resolve about a week after uncomplicated cardiac surgery[5]. Whether or not thoracentesis improves
dyspnea beyond that which is experienced during the typical day – to – day postoperative course is unclear.
The odds ratio for improvement of dyspnea for Cases who had thoracentesis versus age and operation
matched Controls was 3.1. But this was not significant for the limited number of patients studied (p = 0.14,
95% CI 0.7 – 14.5).
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One interpretation of this result could be that thoracentesis doesn’t improve dyspnea compared to the
typical day – to – day postoperative course. For this interpretation, we would offer that reduction of PMN
burden had no impact on dyspnea. Symptomatic improvement after thoracentesis is generally correlated
with increasing volumes of pleural fluid removed[11, 12]. If there is no difference between these groups,
we might explain this by the small size of effusions encountered (median = 0.5 L). However, an alternative
explanation is that the current study was underpowered to detect significant differences between the two
groups. The upper limit of the OR 95% confidence interval is 14.5 in the setting of a trend toward
statistical significance. This large upper limit leads us to believe that the study was in fact, underpowered
to detect a significant difference.

We found no significant difference in LOS for Cases who had thoracentesis versus Controls who did
not (6.7 ± 3.2 days versus 5.8 ± 1.6 days, p=0.84). Therefore, we could not substantiate reports made by
mid-level providers that cardiac surgery patients experience fewer postoperative days in hospital after
thoracentesis. Patient LOS at our institution was observed to be shorter than for similar patients in the
literature (5-7 versus 9-14 days)[64].

An interesting related observation is that Cases who required thoracentesis had a significantly higher
oxygen requirement on POD3 versus matched Controls (mean = 2.7 versus 1.2 LPM, p = 0.02). If patients
who had thoracentesis were more symptomatic than matched Controls, but there was no difference in LOS,
this raises some questions about the role of thoracentesis in their course of recovery. The mean length of
stay from thoracentesis to discharge for Cases was not significantly different versus the equivalent day to
discharge for Controls (2.8 vs. 1.9 days, p = 0.84). Linear regression analysis revealed a significant
positive correlation between LOS and POD of thoracentesis (Coef. of Variation = 2.5, SE = 0.84, p < 0.01).
By this trend, we could predict that patients who had thoracentesis on POD3 would stay 4 days, on POD4
would stay 7 days, and POD5 would stay 9 days. Although we cannot say whether or not thoracentesis
augmented hospital course, there is an argument that this might have been the case.
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We did not observe escalation of care during the study period for either Cases or Controls. Based on
our statistical analysis, the probability that our actual rate of escalation of care is ≤10% can be made with
>95% confidence (p = 0.04, 95% CI 0.00 – 0.14). Although not explicitly an endpoint, there were no
complications of bleeding, infection, or pneumothorax attributable to thoracentesis during the study.

Approximately 30% of inpatient cardiac surgery patients will have postoperative AF[67]. The
current study observed a rate of 33% amongst all patients, which is consistent with the literature. There
was no significant difference between Cases and Controls for the odds of developing postoperative AF
during the present study (3 versus 8 patients, OR = 0.22, p = 0.13). If a patient had postoperative AF, the
mean number of days in AF was also not significantly different between Case and Control patients (2.3
versus 1.8 days, p = 0.45). Sensitivity analysis by the POD of thoracentesis demonstrated that the odds of
postoperative AF were significantly reduced for Cases (0:11) versus matched Controls (6:5) if intervention
was performed before POD5 (p = 0.01). The incidence of AF was also significantly lower for Cases who
underwent thoracentesis prior to POD5 (0 of 11 patients) versus Cases who underwent thoracentesis on
POD5 (3 of 4 patients)(95% CI 0.00 – 0.95, p = 0.05).

The differences in incidence of postoperative AF amongst Cases and Controls might be explained by
several factors.

These include: 1) inpatient medical management, 2) systemic inflammation, 3)

postoperative risk factors, 4) preoperative risk factors, and 5) the study design [e.g. resolution of AF prior
to POD3]. First, the cumulative dosage of amiodarone was not significantly different between groups
during the inpatient period of study (670 versus 730 mg, p = 0.43). Second, there was no difference
observed for markers of systemic inflammation during the study. These included mean WBC (9.8 vs. 9.9 X
103 cells/mL, p < 0.46) and the absence of fever during the inpatient period of study in both groups. Third,
the highest postoperative risk factors for new onset AF after cardiac surgery are pulmonary edema (OR =
5) and pleural effusion requiring thoracentesis (OR = 3)[59]. Although not formally measured, nearly all of
the Cases and Controls had some minor component of pulmonary edema on their POD3 chest x-ray. By
design, only Cases had been determined to require a thoracentesis during the study. We did not find an
increased risk of postoperative AF with the requirement for thoracentesis.
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Fourth, the highest preoperative risk factor for postoperative AF is a prior history of AF[67].
Although the incidence of AF [e.g. chronic or paroxysmal] in the general population is 2 – 4%, the
incidence of preoperative AF for patients undergoing cardiac surgical procedures is approximately
30%[67]. Contributing preoperative risk factors for new onset of postoperative AF include age >75 years
and history of stroke[59, 67]. The mean age of patients in our study was 75 years but this was not different
between Case and Control groups (p = 0.89). However, we did not evaluate prior history of AF or stroke to
account for differences in the risk of postoperative AF. Perhaps preoperative risk might explain the
differences in both incidence and persistence of AF between the two groups after cardiac surgery. Fifth,
additional reasons for not detecting postoperative AF would have been resolution prior to POD3 or
occurrence after POD7.

An alternative explanation for the differences in incidence of AF between Cases and Controls is the
early treatment of pleural effusion. Stamou, et al, have shown that pleural effusion is a risk factor for new
onset AF after cardiac surgery[59]. Pericardial effusion is also a known risk factor for AF and up to 63%
of patients maintain a sub-clinical pericardial effusion 1-week after surgery[60]. Vargas, et al, have
demonstrated that the persistence of pericardial effusion is dependent on the persistence of pleural effusion
after myocardial revascularization[61]. Early treatment of pleural effusion in Cases might therefore explain
the difference in incidence of AF. We have also proposed that early reduction of PMN burden in the
pleural space with thoracentesis might shorten the duration of lung and pleural inflammation. The COPPS2 trial demonstrated a lower incidence of both pleural effusion and atrial fibrillation with the use colchicine
as an anti-inflammatory agent[57]. One of the mechanisms of action for colchicine is reduction in PMN
recruitment[57]. It is reasonable to suspect that reducing PMN recruitment with colchicine would have
reduced PMN burden in the pleural space. Although not definitive, the present study might provide some
evidence that PMN burden in the pleural space is part of the pathogenesis pathway in postoperative AF.

There are several limitations to this study. First, daily peak O2 supplementation was used as a
surrogate marker of changes in dyspnea in the absence of a validated instrument. A validated instrument
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would have presumably produced more precise results. Second, a small number of patients were thought
required to show statistical significance in terms of the major endpoints for this study. We did not power
the study appropriately to show differences for our other endpoints and this was a limitation to interpreting
some of the results. Third, our findings for postoperative AF are interpreted with some hesitation. We did
not evaluate patients for preoperative risk factors for postoperative AF. Preoperative risk could have
explained the differences in both incidence and persistence of AF during the study. Lastly, our study
design was useful in terms of expeditiously completing a low-cost pilot project but the results might not be
readily generalizable to larger populations of cardiac surgery patients.

Several research questions that have emerged from the present study. First, who is appropriate for
thoracentesis after cardiac surgery? Usta, et al, used the size of pleural effusion (> 480mL) estimated by
chest x-ray and thoracic ultrasound in symptomatic patients in order to determine who should undergo
thoracentesis[65]. For smaller symptomatic effusions, patients in their study received diuretics[65]. In our
study, more than half the Cases that improved after thoracentesis had a pleural fluid volume of less than
400mL. Additionally, there is no comparative data to suggest that diuretics are a superior therapy to
thoracentesis for patients with smaller effusions. Diuretics increase the concentration of proteins in the
pleural space as compared to thoracentesis[71]. This could feasibly promote ongoing inflammation and
related pulmonary symptoms after cardiac surgery. Usta’s study also suggests that LOS is longer for
patients who receive diuretics for small effusions[65]. Perhaps the use of diuretics in these small effusions
evolved due to the historically poor complication rate for thoracentesis in the setting of uncertain benefit.
If this is the case, its use in smaller effusions might require some reconsideration given the reduced
complication rate for thoracentesis with thoracic ultrasound.

Second, does thoracentesis augment the postoperative course of patients with non-specific pleural
effusion who require intervention after cardiac surgery? We think that the current report lays some
groundwork for such an outcomes study.

The goals of our study were to measure frequency of

improvement and compare selected outcomes with age and procedure controls. We found that the majority
of patients experience some improvement of dyspnea with thoracentesis but these people might have been
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sicker after surgery. We have further demonstrated that there are increased odds for improved dyspnea for
patients who have thoracentesis versus age and operation matched controls. We did not show significance
for this result, likely because the study was not powered to detect it. We have reported that there is no
difference for LOS between patients who have thoracentesis. A larger study might have also detected a
difference for LOS that favored Controls. Lastly, regression analysis suggested that patients who had
thoracentesis later in their course, stayed longer. We think that there might be a beneficial impact for
thoracentesis in the postoperative course for certain patients who require intervention. But this has yet to
be fully elucidated.

Lastly, is there a role for early thoracentesis (before POD5) in reducing postoperative AF?
Designing an ideal study with generalizable results might be challenging at this point. We can, however,
offer some considerations based on the learning from our current study. First, a prospective study might
enable the use of an instrument that reliably documents preoperative risk factors for postoperative AF. Our
current study would have benefited from an accurate account of preoperative risk factors for AF in
interpreting our results. Second, we might consider broadening the inpatient period of study to encompass
the entire postoperative length of stay. We did not measure postoperative AF prior to POD3 or after POD7
in the current study, which may have biased our results.

Third and as suggested above, a better

understanding of which patients should have intervention might be helpful in determining selection criteria
for an intervention group in a prospective study. Well-defined selection criteria might help determine the
limits of generalizability for reported results. In the current study, it was unclear what the selection criteria
were for thoracentesis and this impacts the generalizability of our reported outcomes data.

8

Conclusions
The present pilot study suggests that the majority of patients who have symptomatic pleural effusion

have some improvement in dyspnea after thoracentesis. This benefit did not translate into reduced length
of stay. Our observations also suggest that patients might experience fewer days in AF with thoracentesis,
particularly if performed earlier in the course of their postoperative care. These observations were limited
to patients with pulmonary symptoms that required thoracentesis based on unclear clinical criteria. We
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interpret these results with some hesitation, primarily because preoperative risk factors for postoperative
AF could have explained differences detected between Cases and Controls. Future research might focus on
better defining the clinical criteria for thoracentesis in non-specific pleural effusion and better
understanding the impact of intervention on postoperative course.

Page 55 of 67

9
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.

References
Hall, M., et al., National Hospital Discharge Survey: 2007 Summary, in National Health
Statistics Reports. 2010, Naitonal Center for Health Statistics: Hyattsville, Maryland. p. 1-24.
Dvir, D., et al., Transcatheter Aortic Valve Replacement for Degenerative Bioprosthetic Surgical
Valves. Circulation, 2012. 126: p. 2335-2344.
Light, R., Pleural Effusions Following Cardiac Injury and Coronary Artery Bypass Graft Surgery.
Sem Resp Crit Care Med, 2001. 22(6): p. 657-663.
Labidi, M., et al., Pleural Effusions Following Cardiac Surgery: Prevalence, Risk Factors, and
Clinical Features. CHEST, 2009. 136: p. 1604-1611.
Light, R., et al., Prevalence and Clinical Course of Pleural Effusions at 30 Days after Coronary
Artery and Cardiac Surgery. Am J Respir Crit Care Med, 2002. 166: p. 1567-1571.
Light, R., et al., Large pleural effusions occuring after coronary artery bypass grafting. Ann
Intern Med, 1999. 130: p. 891-96.
Vargas, F., et al., Relationship Between Pleural Changes after Myocardial Revascularization and
Pulmonary Mechanics. CHEST, 1992. 102: p. 1333-36.
Wynne, R. and M. Botti, Postoperative Pulmonary Dysfunction in Adults After Cardiac Surgery
with Cardiopulmonary Bypass: Clinical Significance and Implications for Practice. Am J Crit
Care, 2004. 13(5): p. 384-393.
Braun, S., M. Birnbaum, and P. Chopra, Abnormalities in Coronary Artery Revascularization
Surgery. CHEST, 1978. 73(3): p. 316-320.
Van Belle, A., et al., Postoperative pulmonary function abnormalities after coronary artery
bypass surery. Resp Med, 1992. 86: p. 1995-199.
Gilmartin, J., A. Wright, and G. Gibson, Effects of pneumothorax or pleural effusion on
pulmonary function. Thorax, 1985. 40: p. 60-65.
Brown, N., N. Zamel, and A. Aberman, Changes in Pulmonary Mechanics and Gas Exchange
following Thoracocentesis. CHEST, 1978. 74(5): p. 540-542.
Rodriguez RM, et al. Prevalence and Clinical Course of Pleural Effusion at 30 days postCoronary Bypass Surgery. in American College of Chest Physicians. 1999. Chicago, IL: American
College of Chest Physicians.
Vargas, F., et al., Actue Pleuropulmonary Complications Detected by Computed Tomography
Following Myocardial Revascularization. Rev Hosp Clin Fac Med S Paulo, 2002. 57(4): p. 135142.
Jensen, L. and L. Yang, Risk factors for postoperative pulmonary complications in coronary
artery bypass graft surgery patients. Eu J Cardiov Nursing, 2007. 6: p. 241-246.
Brody, W. and B. Reitz, Topical Hypothermic Protection of the Myocardium. Ann Thorac Surg,
1975. 20(1): p. 66-71.
Allen, B., et al., Topical cardiac hypothermia in patients with coronary disease. An unnecessary
adjunct to cardioplegic protection and cause of pulmonary morbidity. J Thorac Cardiovasc Surg,
1992. 104(3): p. 626-631.
Nikas, D., F. Ramadan, and J. Elefteriades, Topical Hypothermia: Ineffective and Deleterious as
Adjunct to Cardioplegia for Myocardial Protection. Ann Thorac Surg, 1998. 65(1): p. 28-31.
Landymore, R. and F. Howell, Pulmonary complications following myocardial revascularization
with the internal mammary artery graft. Eur J Cardiothorac Surg, 1990. 4(156-162).
Iverson, L., et al., Injuries to the phrenic nerve resulting in diaphragmatic paralysis with special
reference to stretch trauma. Am J Surg, 1976. 132: p. 263-268.
Mattison, L., et al., Pleural Effusions in the Medical ICU: Prevalence, Causes, and Clinical
Implications. CHEST, 1997. 111: p. 1018-1023.
Stark, P. and A. Leung, Effects of Lobar Atelectasis on the Distribution of Pleural Effusion and
Pneumothorax. J Thorac Imag, 1996. 11: p. 145-149.
Miserocchi, G., Mechanisms controlling the volume of pleural fluid and extravascular lung water.
Eur Respir Rev, 2009. 18(114): p. 244-252.
Kroegel, C. and V. Antony, Immunobiology of pleural inflammation: potential implications for
pathogenesis, diagnosis, and therapy. Eur Respir J, 1997. 10: p. 2411-2418.
Wilcox, P., et al., Phrenic Nerve Function and Its Relationship to Atelectasis After Coronary
Artery Bypass Surgery. CHEST, 1988. 93(4): p. 693-698.

Page 56 of 67

26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.

Zupancich, E., et al., Mechanical ventilation affects inflammatory mediators in patients
undergoing cardiopulmonary bypass for cardiac surgery: A randomized clinical trial. J Thorac
Cardiovasc Surg, 2005. 130(2): p. 378-383.
Paparella, D., T. Yau, and E. Young, Cardiopulmonary bypass induced inflammation:
pathophysiology and treatment. An update. Eu J Cardio Thorac Surg, 2002. 21: p. 232-244.
Bellomo, R., J. Raman, and C. Ronco, Intensive Care Unit Management of the Critically Ill
Patient with Fluid Overload after Open Heart Surgery. Cardiology, 2001. 96: p. 169-176.
Hachenberg, T., et al., Thoracic intravascular and extravascular fluid volumes in cardiac surgical
patients. Anesthesiology, 1993. 79(5): p. 976-984.
Massoudy, P., et al., Evidence for Inflammatory Responses of the Lungs During Coronary Artery
Bypass Grafting with Cardiopulmonary Bypass. CHEST, 2001. 119(1): p. 31-36.
Conti, V., Pulmonary Injury After Cardiopulmonary Bypass. CHEST, 2001. 119(1): p. 2-4.
Wan, S., J. LeClerc, and J. Vincent, Inflammatory Response to Cardiopulmonary Bypass:
Mechanisms Involved and Possible Therapeutic Strategies. CHEST, 1997. 112: p. 676-692.
Roth-Isigkeit, A., et al., Inter-individual differences in cytokine release in patients undergoing
cardiac surgery with cardiopulmonary bypass. Clin Exp Immunol, 2001. 125: p. 80-88.
Gehlbach, B. and E. Geppert, The Pulmonary Manifestations of Left Heart Failure. CHEST, 2004.
125(2): p. 669-682.
Wiener-Kronish, J., et al., Relationship of Pleural Effusions to Increased Permeability Pulmonary
Edema in Anesthetized Sheep. J Clin Invest, 1988. 82: p. 1422-1429.
Wiener-Kronish, J. and M. Matthay, Pleural Effusions Associated with Hydrostatic and Increased
Permeability Pulmonary Edema. CHEST, 1988. 93(4): p. 852-858.
Sadikot, R., et al., Pleural Fluid Characteristics of Patients with Symptomatic Pleural Effusion
After Coronary Artery Bypass Graft Surgery. Arch Intern Med, 2000. 160: p. 2665-2668.
Gilbert, T., G. Barnas, and A. Sequeira, Impact of pleurotomy, continuous positive airway
pressure, and fluid balance during cardiopulmonary bypass on lung mechanics and oxygenation. J
Cardiothorac Vasc Anesth, 1996. 7: p. 844-849.
Taggart, D., et al., Respiratory Dysfunction After Uncomplicated Cardiopulmonary Bypass. Ann
Thorac Surg, 1993. 56: p. 1123-1128.
Utley, J., Pathophysiology of Cardiopulmonary Bypass: A Current Review. AustralAs J Thorac
Surg, 1992. 1(2): p. 46-52.
Martin, W., et al., Respiratory dysfunction and white cell activation following cardiopulmonary
bypass: comparison of membrane and bubble oxygenators. Eu J Cardio Thorac Surg, 1996(10): p.
774-783.
Hurlbut, D., et al., Pleuropulmonary morbidity: internal thoracic artery versus saphenous vein
graft. Ann Thorac Surg, 1990. 50(6): p. 959-964.
Ali, I., P. Lau, and C. Kinley, Opening the pleura during internal mammary artery harvesting:
advantages and disadvantages. Can J Surg, 1996. 39: p. 42-45.
Jain, U., et al., Radiographic pulmonary abnormalities after different types of cardiac surgery. J
Cardiothorac Vasc Anesth, 1991. 5(6): p. 592-595.
Porcel, J. and R. Light, Diagnostic Approach to Pleural Effusion in Adults. Am Fam Physician,
2006. 73: p. 1211-1220.
Ali, H., et al., Spontaneous Hemothorax: A Comprehensive Review. CHEST, 2008. 134: p. 10561065.
Medzhitov, R., Origin and physiology roles of inflammation. Nature, 2008. 454(24): p. 428-435.
Cailhier, J., et al., Resident pleural macrophages are key orchestrators of neutrophil recruitment
in pleural inflammation. Am J Respir Crit Care Med, 2006. 173(5): p. 540-547.
Murai, N., et al., Concurrent evolution and resolution in an acute inflammatory model of rat
carrageenin-induced pleurisy. J Leuk Bio, 2003. 73: p. 456-463.
Murphy, K., Janeway's Immunobiology. 8th ed. 2012, London, England and New York, NY:
Garland Science, Taylor and Francis Group, LLC.
Lo, C., et al., IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian
Cancer. Cancer Res, 2010. 71(2): p. 424-434.
Mutsaers, S., Mesothelial cells: Their structure, function, and role in serosal repair. Respirology,
2002. 7: p. 171-191.
Mutsaers, S., et al., Pathogenesis of pleural fibrosis. Respirology, 2004. 9: p. 428-440.

Page 57 of 67

54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.

Heidecker, J. and S. Sahn, The Spectrum of Pleural Effusions After Coronary Artery Bypass
Grafting Surgery. Clin Chest Med, 2006. 27: p. 267-283.
Imazio, M., The post-pericardiotomy syndrome. Curr Opin Pulm Med, 2012. 18(4): p. 366-74.
Imazio, M., Diagnosis and Management of the Postpericardiotomy Syndrome. Clin Pulm Med,
2014. 21(5): p. 220-4.
Imazio, M., et al., Colchicine for Prevention of Postpericardiotomy Syndrome and Postoperative
Atrial Fibrillation: The COPPS-2 Randomized Clinical Trial. JAMA, 2014. 312(10): p. 10162023.
Molad, Y., Update on Cochicine and It's Mechanism of Action. Curr Rheum Rep, 2002. 4: p. 252256.
Stamou, S., et al., Atrial Fibrillation After Beating Heart Surgery. Am J Cardiology, 2000. 86: p.
64-67.
Ikaheimo, M., et al., Pericardial effusion after cardiac surgery: Incidence, relation to the type of
surgery, antithrombotic therapy, and early coronary bypass graft patency. Am Heart J, 1988.
116(1): p. 97-102.
Vargas, F., et al., Relationship Between Pleural Effusion and Pericardial Involvement After
Myocardial Revascularization. CHEST, 1994. 105(6): p. 1748-1752.
Gibson, A. and M. Segal, A study of the routes by which protein passes from the pericardial cavity
to the blood in rabbits. J Physiol, 1978. 280: p. 423-433.
Bartter, T., et al., Lower Risk and Higher Yield for Thoracentesis When Performed by Experienced
Operators. CHEST, 1993. 103: p. 1873-76.
Lichtenstein, D., et al., Comparative Diagnostic Performances of Auscultation, Chest
Radiography, and Lung Ultrasonography in Acute Respiratory Distress Syndrome.
Anesthesiology, 2004. 100: p. 9-15.
Usta, E., M. Migdat, and G. Ziemer, Ultrasound estimation of volume of postoperative pleural
effusion in cardiac surgery patients. Interactive CardioVasc and Thor Surg, 2010. 10: p. 204-207.
Amar, D., et al., Clinical Prediction Rule for Atrial Fibrillation After Coronary Artery Bypass
Grafting. J Amer Coll Cardio, 2004. 44(6): p. 1248-1253.
Almassi, G., et al., Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg,
1997. 226(4): p. 501-513.
Tremblay, A. and G. Michaud, Single-Center Experience with 250 Tunnelled Pleural Catheter
Insertions for Malignant Pleural Effusion. CHEST, 2006. 129: p. 362-368.
Payne, M., et al., Left Pleural Effusion After Coronary Artery Bypass Decreases With a
Supplemental Pleural Drain. Ann Thorac Surg, 2002. 73: p. 149-152.
Hibbert, R., et al., Safety of Ultrasound-Guided Thoracentesis in Patients with Abnormal
Preprocedural Coagulation Parameters. CHEST, 2013. 144(2): p. 456-463.
Romero-Candeira, S., et al., Influence of Diuretics on the Concentration of Proteins and Other
Components of Pleural Transudates in Patients with Heart Failure. Am J Med, 2001. 110: p. 681686.

Page 58 of 67

10

Appendix A

10.1

Data Abstraction Form
Perioperative Intervention for Post-pericardiotomy Pleural Effusion

Unique Identifier:
10.1.1
1.

_________________________

Baseline Data and Assessment

Patient meets all criteria for study inclusion:

☐ Yes (1)

No (0)

Inclusion Criteria
Patients with radiographically diagnosed pleural effusion are considered. Subjects must meet all of
the following inclusion criteria to be entered into the study:
• Post-primary open cardiac surgery (CABG, valve, CABG + valve, etc.)
• Age 40-85 years
• Diagnosis of postoperative pleural effusion in the perioperative period (< POD7)
2.

Patient meets criteria for study exclusion:

Yes (1)

No (0)

Exclusion Criteria
Any of the following will exclude the subject from study:
• Prior cardiac surgery
• History of pleurodesis
• Patients with pleural effusion known to be associated with non-surgery related
etiology (e.g. pancreatitis, malignancy, etc.)
• Surgical complications (e.g. intraoperative bleeding)
• Maintenance of a (contralateral) chest tube or Pleurex® catheter at diagnosis of
pleural effusion
• INR > 2.5 at the time of thoracentesis
3.

Case or Control Subject

Case (1)

Control (0)

4.

Case Matched Control Number (if Case)

____________________

5.

Age (years)

____________________

6.

Surgical Procedure

o CABG
(0)
o Valve
(1)
o CABG + Valve
(2)
o Other
(3)
If Other, Please Specify:
______________________________
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10.1.2

Cardiopulmonary Recovery

Postoperative
Day (POD)

Max Requirement for
Supplemental O2

Atrial
Fibrillation

Dose of
Amiodarone

Fever
(T>38.3° C)

WBC

Platelets

POD 3

7.
o

8.
o
o

9.

10.
o Yes (1)
o No (0)

11.

12.

_______
X 103
cells/mL

_______
X 103
cells/mL

16.
o Yes (1)
o No (0)

17.

18.

_______
X 103
cells/mL

_______
X 103
cells/mL

22.
o Yes (1)
o No (0)

23.

24.

_______
X 103
cells/mL

_______
X 103
cells/mL

28.
o Yes (1)
o No (0)

29.

30.

_______
X 103
cells/mL

_______
X 103
cells/mL

34.
o Yes (1)
o No (0)

35.

36.

_______
X 103
cells/mL

_______
X 103
cells/mL

40.
o Yes (1)
o No (0)

41.

42.

_______
X 103
cells/mL

_______
X 103
cells/mL

o
o
o
o
o
o
POD 4

POD 5

POD 6

POD 7

Discharge

0 L/min (No
Reqmnt)
(0)
> 0, ≤ 2L/min (1)
> 2, ≤ 4L/min (2)
> 4, ≤ 6L/min (3)
> 6, ≤ 8L/min (4)
> 8, ≤ 10L/min (5)
> 10L/min
(6)

Yes (1)
No (0)

Cum 24hr Dose
(if none,
write 0)

_________mg

13.
o 0 L/min (No
Reqmnt)
(0)
o > 0, ≤ 2L/min (1)
o > 2, ≤ 4L/min (2)
o > 4, ≤ 6L/min (3)
o > 6, ≤ 8L/min (4)
o > 8, ≤ 10L/min (5)
o > 10L/min
(6)

14.
o Yes (1)
o No (0)

19.
o 0 L/min (No
Reqmnt)
(0)
o > 0, ≤ 2L/min (1)
o > 2, ≤ 4L/min (2)
o > 4, ≤ 6L/min (3)
o > 6, ≤ 8L/min (4)
o > 8, ≤ 10L/min (5)
o > 10L/min
(6)

20.
o Yes (1)
o No (0)

25.
o 0 L/min (No
Reqmnt)
(0)
o > 0, ≤ 2L/min (1)
o > 2, ≤ 4L/min (2)
o > 4, ≤ 6L/min (3)
o > 6, ≤ 8L/min (4)
o > 8, ≤ 10L/min (5)
o > 10L/min
(6)

26.
o Yes (1)
o No (0)

31.
o 0 L/min (No
Reqmnt)
(0)
o > 0, ≤ 2L/min (1)
o > 2, ≤ 4L/min (2)
o > 4, ≤ 6L/min (3)
o > 6, ≤ 8L/min (4)
o > 8, ≤ 10L/min (5)
o > 10L/min
(6)

32.
o Yes (1)
o No (0)

37.
o 0 L/min (No
Reqmnt)
(0)
o > 0, ≤ 2L/min (1)
o > 2, ≤ 4L/min (2)
o > 4, ≤ 6L/min (3)
o > 6, ≤ 8L/min (4)
o > 8, ≤ 10L/min (5)
o > 10L/min
(6)

38.
o Yes (1)
o No (0)

15.

Cum 24hr Dose
(if none,
write 0)

_________mg

21.

Cum 24hr Dose
(if none,
write 0)

_________mg

27.

Cum 24hr Dose
(if none,
write 0)

_________mg

33.

Cum 24hr Dose
(if none,
write 0)

_________mg

39.

Cum 24hr Dose
(if none,
write 0)

_________mg

43.

Cases: POD of Thoracentesis

POD:

________________

44.

Cases: Pleural Fluid Volume Removed

Volume: ________________ mL
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10.1.3

Postoperative Course

45. Length of Postoperative Inpatient Stay:

________________ Days

46. Requirement for Escalation of Care:

q Yes (1)
q No (0)

47. Discharge O2 Requirement:

________________ L/min
(if none, write 0)

10.1.4

Post-Discharge Course

48. Diagnosis of post-pericardiotomy syndrome:

q Yes (1)
q No (0)

49. Death (within 30-days):

q Yes (1)
q No (0)

50. Requirement for hospital re-admission:

q Yes (1)
q No (0)

51. Requirement for outpatient procedural management of
pleural effusion:

q Yes (1)
q No (0)
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Appendix B

11.1

STATA Do-Command Program for Data Analysis

Study: Thoracentesis in Cardiac Surgery Patients with Non-Specific Pleural Effusion
Written by David R. Kull, MPH
* Start Program
window stopbox rusure "WARNING: The following program
is designed to run in a specific file structure on one specific
computer. Continue?"
clear
* System Memory Allocation
set memory 1000000
* Clear Data in Memory and Settings
clear all
capture log close
set more off
* Save Data and Log
log using "/Users/davidkull/Desktop/Pericardiotomy - Pleural
Effusion MGMT/DATA/ppcpe.log", replace
* Import PPCPE CSV Delimited TXT File
insheet using "/Users/davidkull/Desktop/Pericardiotomy Pleural Effusion MGMT/DATA/PPCPE.csv"
* Label Imported Variables
label var id_case "Case ID"
label var age_case "Case Age"
label var proc_case "Case Procedure"
label var pod2_o2_case "Case POD2 O2 Requirement"
label var pod3_o2_case "Case POD3 O2 Requirement"
label var pod3_af_case "Case POD3 Atrial Fibrillation"
label var pod3_amio_case "Case POD3 Cumulative
Amiodarone Requirement"
label var pod3_fev_case "Case POD3 Fever"
label var pod3_wbc_case "Case POD3 White Cell Count"
label var pod3_plts_case "Case POD3 Platelets"
label var pod4_o2_case "Case POD4 O2 Requirement"
label var pod4_af_case "Case POD4 Atrial Fibrillation"
label var pod4_amio_case "Case POD4 Cumulative
Amiodarone Requirement"
label var pod4_fev_case "Case POD4 Fever"
label var pod4_wbc_case "Case POD4 White Cell Count"
label var pod4_plts_case "Case POD4 Platelets"
label var pod5_o2_case "Case POD5 O2 Requirement"
label var pod5_af_case "Case POD5 Atrial Fibrillation"
label var pod5_amio_case "Case POD5 Cumulative
Amiodarone Requirement"
label var pod5_fev_case "Case POD5 Fever"
label var pod5_wbc_case "Case POD5 White Cell Count"
label var pod5_plts_case "Case POD5 Platelets"
label var pod6_o2_case "Case POD6 O2 Requirement"
label var pod6_af_case "Case POD6 Atrial Fibrillation"
label var pod6_amio_case "Case POD6 Cumulative
Amiodarone Requirement"
label var pod6_fev_case "Case POD6 Fever"
label var pod6_wbc_case "Case POD6 White Cell Count"

label var pod6_plts_case "Case POD6 Platelets"
label var pod7_o2_case "Case POD7 O2 Requirement"
label var pod7_af_case "Case POD7 Atrial Fibrillation"
label var pod7_amio_case "Case POD7 Cumulative
Amiodarone Requirement"
label var pod7_fev_case "Case POD7 Fever"
label var pod7_wbc_case "Case POD7 White Cell Count"
label var pod7_plts_case "Case POD7 Platelets"
label var dis_o2_case "Case Discharge O2 Requirement"
label var dis_af_case "Case Discharge Atrial Fibrillation"
label var dis_amio_case "Case Discharge Cumulative
Amiodarone Requirement"
label var dis_fev_case "Case Discharge Fever"
label var dis_wbc_case "Case Discharge White Cell Count"
label var dis_plts_case "Case Discharge Platelets"
label var pod_int_case "Case POD Intervention"
label var case_vol_case "Case Volume Pleural Fluid"
label var los_case "Case Length of Stay"
label var escal_case "Case Escalation of Care"
label var dis_o2req_case "Case Discharged on O2"
label var ppcs_case "Case Post Pericardiotomy Syndrome"
label var death_case "Case Death"
label var readmit_case "Case Readmission"
label var out_mgmt_case "Case Req for Outpatient
Management"
label var id_control "Control ID"
label var age_control "Control Age"
label var proc_control "Control Procedure"
label var pod2_o2_control "Control POD2 O2 Requirement"
label var pod3_o2_control "Control POD3 O2 Requirement"
label var pod3_af_control "Control POD3 Atrial Fibrillation"
label var pod3_amio_control "Control POD3 Cumulative
Amiodarone Requirement"
label var pod3_fev_control "Control POD3 Fever"
label var pod3_wbc_control "Control POD3 White Cell
Count"
label var pod3_plts_control "Control POD3 Platelets"
label var pod4_o2_control "Control POD4 O2 Requirement"
label var pod4_af_control "Control POD4 Atrial Fibrillation"
label var pod4_amio_control "Control POD4 Cumulative
Amiodarone Requirement"
label var pod4_fev_control "Control POD4 Fever"
label var pod4_wbc_control "Control POD4 White Cell
Count"
label var pod4_plts_control "Control POD4 Platelets"
label var pod5_o2_control "Control POD5 O2 Requirement"
label var pod5_af_control "Control POD5 Atrial Fibrillation"
label var pod5_amio_control "Control POD5 Cumulative
Amiodarone Requirement"
label var pod5_fev_control "Control POD5 Fever"
label var pod5_wbc_control "Control POD5 White Cell
Count"
label var pod5_plts_control "Control POD5 Platelets"
label var pod6_o2_control "Control POD6 O2 Requirement"
label var pod6_af_control "Control POD6 Atrial Fibrillation"
label var pod6_amio_control "Control POD6 Cumulative
Amiodarone Requirement"
label var pod6_fev_control "Control POD6 Fever"
label var pod6_wbc_control "Control POD6 White Cell
Count"
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label var pod6_plts_control "Control POD6 Platelets"
label var pod7_o2_control "Control POD7 O2 Requirement"
label var pod7_af_control "Control POD7 Atrial Fibrillation"
label var pod7_amio_control "Control POD7 Cumulative
Amiodarone Requirement"
label var pod7_fev_control "Control POD7 Fever"
label var pod7_wbc_control "Control POD7 White Cell
Count"
label var pod7_plts_control "Control POD7 Platelets"
label var dis_o2_control "Control Discharge O2
Requirement"
label var dis_af_control "Control Discharge Atrial
Fibrillation"
label var dis_amio_control "Control Discharge Cumulative
Amiodarone Requirement"
label var dis_fev_control "Control Discharge Fever"
label var dis_wbc_control "Control Discharge White Cell
Count"
label var dis_plts_control "Control Discharge Platelets"
label var pod_int_control "Control POD Intervention"
label var case_vol_control "Control Volume Pleural Fluid"
label var los_control "Control Length of Stay"
label var escal_control "Control Escalation of Care"
label var dis_o2req_control "Control Discharged on O2"
label var ppcs_control "Control Post Pericardiotomy
Syndrome"
label var death_control "Control Death"
label var readmit_control "Control Readmission"
label var out_mgmt_control "Control Req for Outpatient
Management"
label var mean_wbc_case "Mean WBC Cases"
label var mean_wbc_control "Mean WBC Control"

label values dis_af_control yn_lbl
label values dis_fev_case yn_lbl
label values dis_fev_control yn_lbl

* Label Data from Imported Variables

label values pod3_o2_control o2_lbl
label values pod4_o2_control o2_lbl
label values pod5_o2_control o2_lbl
label values pod6_o2_control o2_lbl
label values pod7_o2_control o2_lbl
label values dis_o2_control o2_lbl

capture label drop proc_lbl
label define proc_lbl 0 "CABG" 1 "Valve" 2
"CABG+VALVE" 3 "Other"
label values proc_case proc_lbl
label values proc_control proc_lbl
capture label drop yn_lbl
label define yn_lbl 0 "No" 1 "Yes"
label values pod3_af_case yn_lbl
label values pod3_af_control yn_lbl
label values pod3_fev_case yn_lbl
label values pod3_fev_control yn_lbl
label values pod4_af_case yn_lbl
label values pod4_af_control yn_lbl
label values pod4_fev_case yn_lbl
label values pod4_fev_control yn_lbl
label values pod5_af_case yn_lbl
label values pod5_af_control yn_lbl
label values pod5_fev_case yn_lbl
label values pod5_fev_control yn_lbl
label values pod6_af_case yn_lbl
label values pod6_af_control yn_lbl
label values pod6_fev_case yn_lbl
label values pod6_fev_control yn_lbl
label values pod7_af_case yn_lbl
label values pod7_af_control yn_lbl
label values pod7_fev_case yn_lbl
label values pod7_fev_control yn_lbl
label values dis_af_case yn_lbl

label values escal_case yn_lbl
label values escal_control yn_lbl
label values ppcs_case yn_lbl
label values ppcs_control yn_lbl
label values death_case yn_lbl
label values death_control yn_lbl
label values readmit_case yn_lbl
label values readmit_control yn_lbl
label values out_mgmt_case yn_lbl
label values out_mgmt_control yn_lbl
capture label drop o2_lbl
label define o2_lbl 0 "No O2 Requirement" 1 ">0, <=2 L/min
O2 Requirement" 2 ">2, <=4 L/min O2 Requirement" 3 ">4,
<=6 L/min O2 Requirement" 4 ">6, <=8 L/min O2
Requirement" 5 ">8, <=10 L/min O2 Requirement" 6 ">10
L/min O2 Requirement"
label values pod3_o2_case o2_lbl
label values pod4_o2_case o2_lbl
label values pod5_o2_case o2_lbl
label values pod6_o2_case o2_lbl
label values pod7_o2_case o2_lbl
label values dis_o2_case o2_lbl

* Generate and Label Pre- post-Intervention Daily Peak O2
Requirement for Cases
capture drop o2_pre_case
gen o2_pre_case = 0
label var o2_pre_case "Case pre-Intervention Peak O2
Requirement"
replace o2_pre_case = pod2_o2_case if pod_int_case==3
replace o2_pre_case = pod3_o2_case if pod_int_case==4
replace o2_pre_case = pod4_o2_case if pod_int_case==5
replace o2_pre_case = pod5_o2_case if pod_int_case==6
replace o2_pre_case = pod6_o2_case if pod_int_case==7
capture drop o2_post_case
gen o2_post_case = 0
label var o2_post_case "Case post-Intervention Peak O2
Requirement"
replace o2_post_case = pod4_o2_case if pod_int_case==3
replace o2_post_case = pod5_o2_case if pod_int_case==4
replace o2_post_case = pod6_o2_case if pod_int_case==5
replace o2_post_case = pod7_o2_case if pod_int_case==6
capture drop o2_diff_case
gen o2_diff_case = ((o2_post_case - o2_pre_case)*2)
label var o2_diff_case "Case Pre-/Post-Int Peak O2
Supplement Difference"
label values o2_pre_case o2_lbl
label values o2_post_case o2_lbl
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capture drop o2_status_case
gen o2_status_case = 0
label var o2_status_case "Case Pre-/Post-Int Status Change"
replace o2_status_case = 0 if (o2_post_case o2_pre_case)==0
replace o2_status_case = 1 if (o2_post_case - o2_pre_case)<0
replace o2_status_case = -1 if (o2_post_case o2_pre_case)>0
label define imp_lbl 0 "No Change" 1 "Improved Dyspnea" 1 "Worsened Dyspnea"
label values o2_status_case imp_lbl
capture drop wdyspnea_case
gen wdyspnea_case = 0
replace wdyspnea_case = 1 if (o2_post_case o2_pre_case)>0
label var wdyspnea_case "Worsened Dyspnea"
capture drop ncdyspnea_case
gen ncdyspnea_case = 0
replace ncdyspnea_case = 1 if (o2_post_case o2_pre_case)==0
label var ncdyspnea_case "No Change"
capture drop idyspnea_case
gen idyspnea_case = 0
replace idyspnea_case = 1 if (o2_post_case - o2_pre_case)<0
label var idyspnea_case "Improved Dyspnea"
* Generate and Label Pre- post-Intervention Daily Peak O2
Requirement for Controls
capture drop o2_pre_control
gen o2_pre_control = 0
label var o2_pre_control "Control pre-Intervention Peak O2
Requirement"
replace o2_pre_control = pod2_o2_control if
pod_int_control==3
replace o2_pre_control = pod3_o2_control if
pod_int_control==4
replace o2_pre_control = pod4_o2_control if
pod_int_control==5
replace o2_pre_control = pod5_o2_control if
pod_int_control==6
replace o2_pre_control = pod6_o2_control if
pod_int_control==7
capture drop o2_post_control
gen o2_post_control = 0
label var o2_post_control "Control post-Intervention Peak O2
Requirement"
replace o2_post_control = pod4_o2_control if
pod_int_control==3
replace o2_post_control = pod5_o2_control if
pod_int_control==4
replace o2_post_control = pod6_o2_control if
pod_int_control==5
replace o2_post_control = pod7_o2_control if
pod_int_control==6
capture drop o2_diff_control
gen o2_diff_control = ((o2_post_control o2_pre_control)*2)
label var o2_diff_control "Control Equiv. Peak O2
Supplement Difference"
label values o2_pre_control o2_lbl
label values o2_post_control o2_lbl

capture drop o2_status_control
gen o2_status_control = 0
label var o2_status_control "Control Pre-/Post- Equiv. Status
Change"
replace o2_status_control = 0 if (o2_post_control o2_pre_control)==0
replace o2_status_control = 1 if (o2_post_control o2_pre_control)<0
replace o2_status_control = -1 if (o2_post_control o2_pre_control)>0
label values o2_status_control imp_lbl
capture drop wdyspnea_control
gen wdyspnea_control = 0
replace wdyspnea_control = 1 if (o2_post_control o2_pre_control)>0
label var wdyspnea_control "Worsened Dyspnea"
capture drop ncdyspnea_control
gen ncdyspnea_control = 0
replace ncdyspnea_control = 1 if (o2_post_control o2_pre_control)==0
label var ncdyspnea_control "No Change"
capture drop idyspnea_control
gen idyspnea_control = 0
replace idyspnea_control = 1 if (o2_post_control o2_pre_control)<0
label var idyspnea_control "Improved Dyspnea"
* Generate Mean LOS after Intervention (or Equiv) for
Cases and Controls
capture drop mlos_case
gen mlos_case = los_case - pod_int_case
label var mlos_case "Post Intervention Length of Stay
(Case)"
capture drop mlos_control
gen mlos_control = los_control - pod_int_control
label var mlos_control "Equivalent Length of Stay (Control)"
* Generate and Label POD_INT + 1d (or Equivalent)
Variables for Cases and Controls
capture drop pod_equiv_o2_case
gen pod_equiv_o2_case = 0
capture drop pod_equiv_af_case
gen pod_equiv_af_case = 0
capture drop pod_equiv_amio_case
gen pod_equiv_amio_case = 0
capture drop pod_equiv_fev_case
gen pod_equiv_fev_case = 0
capture drop pod_equiv_wbc_case
gen pod_equiv_wbc_case = 0
capture drop pod_equiv_plts_case
gen pod_equiv_plts_case = 0
replace pod_equiv_o2_case = pod4_o2_case if pod_int_case
== 3
replace pod_equiv_af_case = pod4_af_case if pod_int_case
== 3
replace pod_equiv_amio_case = pod4_amio_case if
pod_int_case == 3
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replace pod_equiv_fev_case = pod4_fev_case if
pod_int_case == 3
replace pod_equiv_wbc_case = pod4_wbc_case if
pod_int_case == 3
replace pod_equiv_plts_case = pod4_plts_case if
pod_int_case == 3

replace pod_equiv_fev_control = pod4_fev_control if
pod_int_control == 3
replace pod_equiv_wbc_control = pod4_wbc_control if
pod_int_control == 3
replace pod_equiv_plts_control = pod4_plts_control if
pod_int_control == 3

replace pod_equiv_o2_case = pod5_o2_case if pod_int_case
== 4
replace pod_equiv_af_case = pod5_af_case if pod_int_case
== 4
replace pod_equiv_amio_case = pod5_amio_case if
pod_int_case == 4
replace pod_equiv_fev_case = pod5_fev_case if
pod_int_case == 4
replace pod_equiv_wbc_case = pod5_wbc_case if
pod_int_case == 4
replace pod_equiv_plts_case = pod5_plts_case if
pod_int_case == 4

replace pod_equiv_o2_control = pod5_o2_control if
pod_int_control == 4
replace pod_equiv_af_control = pod5_af_control if
pod_int_control == 4
replace pod_equiv_amio_control = pod5_amio_control if
pod_int_control == 4
replace pod_equiv_fev_control = pod5_fev_control if
pod_int_control == 4
replace pod_equiv_wbc_control = pod5_wbc_control if
pod_int_control == 4
replace pod_equiv_plts_control = pod5_plts_control if
pod_int_control == 4

replace pod_equiv_o2_case = pod6_o2_case if pod_int_case
== 5
replace pod_equiv_af_case = pod6_af_case if pod_int_case
== 5
replace pod_equiv_amio_case = pod6_amio_case if
pod_int_case == 5
replace pod_equiv_fev_case = pod6_fev_case if
pod_int_case == 5
replace pod_equiv_wbc_case = pod6_wbc_case if
pod_int_case == 5
replace pod_equiv_plts_case = pod6_plts_case if
pod_int_case == 5

replace pod_equiv_o2_control = pod6_o2_control if
pod_int_control == 5
replace pod_equiv_af_control = pod6_af_control if
pod_int_control == 5
replace pod_equiv_amio_control = pod6_amio_control if
pod_int_control == 5
replace pod_equiv_fev_control = pod6_fev_control if
pod_int_control == 5
replace pod_equiv_wbc_control = pod6_wbc_control if
pod_int_control == 5
replace pod_equiv_plts_control = pod6_plts_control if
pod_int_control == 5

replace pod_equiv_o2_case = pod7_o2_case if pod_int_case
== 6
replace pod_equiv_af_case = pod7_af_case if pod_int_case
== 6
replace pod_equiv_amio_case = pod7_amio_case if
pod_int_case == 6
replace pod_equiv_fev_case = pod7_fev_case if
pod_int_case == 6
replace pod_equiv_wbc_case = pod7_wbc_case if
pod_int_case == 6
replace pod_equiv_plts_case = pod7_plts_case if
pod_int_case == 6

replace pod_equiv_o2_control = pod7_o2_control if
pod_int_control == 6
replace pod_equiv_af_control = pod7_af_control if
pod_int_control == 6
replace pod_equiv_amio_control = pod7_amio_control if
pod_int_control == 6
replace pod_equiv_fev_control = pod7_fev_control if
pod_int_control == 6
replace pod_equiv_wbc_control = pod7_wbc_control if
pod_int_control == 6
replace pod_equiv_plts_control = pod7_plts_control if
pod_int_control == 6

capture drop pod_equiv_o2_control
gen pod_equiv_o2_control = 0

label var pod_equiv_o2_case "Case - Peak O2 Req."
label var pod_equiv_o2_control "Control - Peak Equiv O2
Req."

capture drop pod_equiv_af_control
gen pod_equiv_af_control = 0
capture drop pod_equiv_amio_control
gen pod_equiv_amio_control = 0
capture drop pod_equiv_fev_control
gen pod_equiv_fev_control = 0
capture drop pod_equiv_wbc_control
gen pod_equiv_wbc_control = 0
capture drop pod_equiv_plts_control
gen pod_equiv_plts_control = 0
replace pod_equiv_o2_control = pod4_o2_control if
pod_int_control == 3
replace pod_equiv_af_control = pod4_af_control if
pod_int_control == 3
replace pod_equiv_amio_control = pod4_amio_control if
pod_int_control == 3

label values pod_equiv_o2_case o2_lbl
label values pod_equiv_o2_control o2_lbl
label values pod_equiv_af_case yn_lbl
label values pod_equiv_af_control yn_lbl
label values pod_equiv_fev_case yn_lbl
label values pod_equiv_fev_control yn_lbl
* Generate and Label Days of AF for Cases and Controls
capture drop daf_case
gen daf_case = pod3_af_case + pod4_af_case +
pod5_af_case + pod6_af_case + pod7_af_case
label var daf_case "Case Days in AF"
capture drop daf_control
gen daf_control = pod3_af_control + pod4_af_control +
pod5_af_control + pod6_af_control + pod7_af_control
label var daf_control "Control Days in AF"
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* Generate and Label Pre- and Post-Intervention Days of AF
for Cases and Controls
capture drop daf_post_case
gen daf_post_case = 0
replace daf_post_case = pod4_af_case + pod5_af_case +
pod6_af_case + pod7_af_case if pod_int_case==3
replace daf_post_case = pod5_af_case + pod6_af_case +
pod7_af_case if pod_int_case==4
replace daf_post_case = pod6_af_case + pod7_af_case if
pod_int_case==5
replace daf_post_case = pod7_af_case if pod_int_case==6
capture drop daf_post_control
gen daf_post_control = 0
replace daf_post_control = pod4_af_control +
pod5_af_control + pod6_af_control + pod7_af_control if
pod_int_control==3
replace daf_post_control = pod5_af_control +
pod6_af_control + pod7_af_control if pod_int_control==4
replace daf_post_control = pod6_af_control +
pod7_af_control if pod_int_control==5
replace daf_post_control = pod7_af_control + dis_af_control
if pod_int_control==6
capture drop daf_pre_case
gen daf_pre_case = 0
replace daf_pre_case = daf_case - daf_post_case +
pod3_af_case if pod_int_case==3
replace daf_pre_case = daf_case - daf_post_case +
pod4_af_case if pod_int_case==4
replace daf_pre_case = daf_case - daf_post_case +
pod5_af_case if pod_int_case==5
replace daf_pre_case = daf_case - daf_post_case +
pod6_af_case if pod_int_case==6
replace daf_pre_case = daf_case - daf_post_case +
pod7_af_case if pod_int_case==7
capture drop daf_pre_control
gen daf_pre_control = 0
replace daf_pre_control = daf_control - daf_post_control +
pod3_af_control if pod_int_control==3
replace daf_pre_control = daf_control - daf_post_control +
pod4_af_control if pod_int_control==4
replace daf_pre_control = daf_control - daf_post_control +
pod5_af_control if pod_int_control==5
replace daf_pre_control = daf_control - daf_post_control +
pod6_af_control if pod_int_control==6
replace daf_pre_control = daf_control - daf_post_control +
pod7_af_control if pod_int_control==7
label var daf_post_case "Case Days AF post-Intervention"
label var daf_pre_case "Case Days AF pre-Intervention"
label var daf_post_control "Control Days AF postIntervention"
label var daf_pre_control "Control Days AF preIntervention"
* Generate and Label Post-Intervention Cumulative Doses of
Amiodarone
capture drop amio_post_case
gen amio_post_case = 0
replace amio_post_case = pod4_amio_case +
pod5_amio_case + pod6_amio_case + pod7_amio_case if
pod_int_case==3
replace amio_post_case = pod5_amio_case +
pod6_amio_case + pod7_amio_case if pod_int_case==4
replace amio_post_case = pod6_amio_case +
pod7_amio_case if pod_int_case==5

replace amio_post_case = pod7_amio_case if
pod_int_case==6
capture drop amio_post_control
gen amio_post_control = 0
replace amio_post_control = pod4_amio_control +
pod5_amio_control + pod6_amio_control +
pod7_amio_control if pod_int_control==3
replace amio_post_control = pod5_amio_control +
pod6_amio_control + pod7_amio_control if
pod_int_control==4
replace amio_post_control = pod6_amio_control +
pod7_amio_control if pod_int_control==5
replace amio_post_control = pod7_amio_control +
dis_amio_control if pod_int_control==6
label var amio_post_case "Case Total Post-Intervention
Amiodarone"
label var amio_post_control "Control Total Post-Intervention
Amiodarone"
* Data Generation and Labeling Complete; Ready for
Endpoints
window stopbox rusure "Variable Generation and Labeling
Complete. Display Endpoints?"
******************************
** Demographic and Baseline **
******************************
tab proc_case
ttest age_case==age_control
window stopbox rusure "Demogrpahic and Baseline Results
Generated. Click Yes to Continue or No to Review"
**********************
** Primary Endpoint **
**********************
* Frequency of Improved Dyspnea Following Thoracentesis
tab o2_status_case
tab o2_status_control
* Binomial Expansion Test for Improvement >50%
bitest idyspnea_case == 0.5
ci idyspnea_case, binomial
* POD of Intervention
tab pod_int_case pod_int_control
* Regression for Pleural Fluid Removed
summarize case_vol_case, detail
regress case_vol_case los_case
regress case_vol_case o2_diff_case
* Fisher's Exact Test on Improvement Status
tabulate o2_status_case o2_status_control, exact
* Difference in O2 Requirement after Thoracentesis for
Cases and Controls
window stopbox rusure "Primary Endpoint Results
Generated. Click Yes to Continue or No to Review"
************************
** Secondary Endpoint **
************************
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* Summary of Data
summarize los_case los_control

* 30-day Mortality
ttest death_case==death_control

* Total Days in Hospital by Group
tab los_case
tab los_control

* Pre- Post- Thoracentesis Oxygen Requirement for Cases
ttest o2_pre_case==o2_post_case if pod_int_case>=4

* Paired T-test of Hospital LOS
ttest los_case==los_control
* Regression Analysis of LOS by POD of Thoracentesis
regress los_case pod_int_case
* Mean LOS from Intervention to Discharge (Cases Only)
sum mlos_case
sum mlos_case if pod_int_case<5
window stopbox rusure "Secondary Endpoint Results
Generated. Click Yes to Continue or No to Review"
***********************
** Tertiary Endpoint **
***********************

* Save Data
save "/Users/davidkull/Desktop/Pericardiotomy - Pleural
Effusion MGMT/DATA/ppcpe_dataset", replace
set more off
***************************
** Automated Key Figures **
***************************
* Primary Endpoint Graph 3
graph twoway (scatter case_vol_case los_case) (lfit
case_vol_case los_case)
graph export "/Users/davidkull/Desktop/Pericardiotomy Pleural Effusion MGMT/DATA/Graphs/dysp3.tif", replace

ttest escal_case==escal_control
* Secondary Endpoint Graph
window stopbox rusure "Tertiary Endpoint Results
Generated. Click Yes to Continue or No to Review"
******************************
** Other Endpoint Summaries **
******************************
*************************
** Atrial Fibrillation **
*************************
* Days in AF
tab daf_case pod_int_case
summarize daf_case if daf_case>0
summarize daf_control if daf_control>0
* Days in AF if POD of Thoracentesis <5
summarize daf_case if daf_case>0 & pod_int_case<5
summarize daf_control if daf_control>0 & pod_int_case<5

graph box los_case los_control, ytitle(Days) ytick(##10)
ymtick(##2) ylabel(#10)
graph export "/Users/davidkull/Desktop/Pericardiotomy Pleural Effusion MGMT/DATA/Graphs/los.tif", replace
* Primary Endpoint Graph 1
clear
insheet using "/Users/davidkull/Desktop/Pericardiotomy Pleural Effusion MGMT/DATA/PPCPE2.csv"
label var case_status "Case or Control"
label var dysp_status "Dyspnea Change"
label var mean "Proportion"
label var n "Number of Patients"
capture label drop case_lbl
label define case_lbl 1 "Case" 2 "Control"
label values case_status case_lbl

* Requirement for Amiodarone After Thoracentesis
ttest amio_post_case==amio_post_control
ttest amio_post_case==amio_post_control if pod_int_case<5

capture label drop dysp_lbl
label define dysp_lbl 1 "Improved Dyspnea" 2 "No Change"
3 "Worsened Dyspnea"
label values dysp_status dysp_lbl

* Markers of SIRS or Acute Phase Reaction
summarize mean_wbc_case, detail
summarize mean_wbc_control, detail
ttest mean_wbc_case==mean_wbc_control
ttest pod_equiv_wbc_case==pod_equiv_wbc_control
* Requirement for Readmission or Outpatient Pleural
Effusion MGMT
ttest readmit_case==readmit_control
ttest out_mgmt_case==out_mgmt_control

generate hidysp = mean + (invttail(n-1,0.025)*(sd / sqrt(n)))
generate lodysp = mean - (invttail(n-1,0.025)*(sd / sqrt(n)))
replace hidysp = 0.9108 in 1
replace lodysp = 0.4483 in 1
replace hidysp = .7258 in 2
replace lodysp = .2228 in 2
replace hidysp = .7258 in 4
replace lodysp = .2228 in 4
replace hidysp = .4162 in 3
replace lodysp = .0234 in 3
replace hidysp = .4162 in 5
replace lodysp = .0234 in 5
replace hidysp = .3397 in 6
replace lodysp = .0035 in 6

* Incidence of Post Pericardiotomy Syndrome
ttest ppcs_case==ppcs_control

generate rank = case_status
if dysp_status == 1
replace rank = case_status+2 if dysp_status == 2
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replace rank = case_status+4 if dysp_status == 3
sort rank
list rank dysp_status case_status, sepby(case_status)
graph twoway (bar mean rank if case_status==1) (bar mean
rank if case_status==2)(rcap hidysp lodysp rank),
legend(row(1) order(1 "Case" 2 "Control")) xlabel( 1.5
"Improved Dyspnea" 3.5 "No Change" 5.5 "Worsened
Dyspnea", noticks) xtitle("Changes in Dyspnea")
ytitle("Proportion of Patients")
graph export "/Users/davidkull/Desktop/Pericardiotomy Pleural Effusion MGMT/DATA/Graphs/dysp.tif", replace
save "/Users/davidkull/Desktop/Pericardiotomy - Pleural
Effusion MGMT/DATA/ppcpe_dataset_graph1", replace
set more off
* Primary Endpoint Graph 2
clear
insheet using "/Users/davidkull/Desktop/Pericardiotomy Pleural Effusion MGMT/DATA/PPCPE3.csv"
label var case_status "Case or Control"
label var pre_post "Pre or Post"
label var mean "Mean"
label var sd "Standard Deviation"
label var n "n"
capture label drop case_lbl
label define case_lbl 1 "Case" 2 "Control"
label values case_status case_lbl
capture label drop pre_post_lbl
label define pre_post_lbl 1 "Pre-Intervention or Equiv" 2
"Post-Intervention or Equiv"
label values pre_post pre_post_lbl
generate hici = mean + (invttail(n-1,0.025)*(sd / sqrt(n)))
generate loci = mean - (invttail(n-1,0.025)*(sd / sqrt(n)))
graph twoway (bar mean rank if pre_post==1) (bar mean
rank if pre_post==2)(rcap hici loci rank), legend(row(1)
order(1 "Pre-Intervention or Equiv" 2 "Post-Intervention or
Equiv")) xlabel( 1.5 "Cases" 3.5 "Controls", noticks)
xtitle("Grouping") ytitle("Daily Peak O2 Requirement")
graph export "/Users/davidkull/Desktop/Pericardiotomy Pleural Effusion MGMT/DATA/Graphs/dysp2.tif", replace
* Close log
log close
* Save Data
save "/Users/davidkull/Desktop/Pericardiotomy - Pleural
Effusion MGMT/DATA/ppcpe_dataset_graph", replace
set more off

